Mutated genes for the catalytic protein of oplophorus luciferase and use thereof

ABSTRACT

Luciferases which are different from those known heretofore have been desired. A luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from the group consisting of valine at the position of 44, alanine at the position of 54 and tyrosine at the position of 138 is substituted with other amino acid(s) in the amino acid sequence of SEQ ID NO: 2.

TECHNICAL FIELD

The present invention relates to mutated genes for the catalytic proteinof Oplophorus luciferase use thereof and so on.

BACKGROUND OF INVENTION

Bioluminescence is a phenomenon based on a chemical reaction in vivo,which is called a luciferin (a luminescence substrate)-luciferase (anenzyme that catalyzes the luminescence reaction) reaction. Numerousstudies of the identification of luciferins or luciferases and theelucidation of the luminescence mechanism in a molecular level have beenperformed for a long time in the country and overseas. In bioluminescentmarine organisms, Oplophorus gracilirostris luciferase from the deep-seashrimp is an extracellularly secreted luciferase (Non-Patent Document1). Oplophorus luciferase is a 106 kDa protein composed of a proteinwith a molecular weight of 35 kDa and a protein with a molecular weightof 19 kDa. The domain that catalyzes the luminescence reaction is foundto be 19 kDa protein. Oplophorus luciferase uses coelenterazine as aluminescence substrate and is classified as a coelenterazine-typeluciferase (Patent Document 1, Non-Patent Document 2). Oplophorusluciferase is different from other coelenterazine-type luciferases inbroad substrate specificity and uses coelenterazine analogues as asuitable substrate as well as coelenterazine (Non-Patent Document 2).When the gene for the 19 kDa protein is expressed in Escherichia coli(E. coli) at ordinary and lower temperatures, the protein is expressedmostly as an insoluble protein (Non-Patent Document 3). When the 19 kDaprotein was expressed as a fusion protein to ZZ domain from protein A ina low temperature expression system, the fused protein could beexpressed as a soluble protein (Non-Patent Document 4). It is reportedthat when the 19 kDa protein was expressed in animal cultured cells, theexpressed protein was hardly secreted outside of cells (Non-PatentDocument 2).

Recently, it is reported that the mutated 19 kDa protein havingcatalytic activity of luminescence was prepared by mutating the 16 aminoacids of the 19 kDa protein and showed higher luminescence activity thannative 19 kDa protein, and was secreted into an extracellular medium(Patent Document 2, Non-Patent Documents 4 and 5). It is also reportedthat coelenterazine derivatives displayed higher activity than nativecoelenterazine used as a substrate (Non-Patent Documents 4 and 5).

In the luminescence reaction system using coelenterazine as a substratefor the luminescence reaction, the luminescence reaction of luciferasaeproceeds only by a substrate and molecular oxygen. For this reason, acoelenterazine-type luciferase gene is used widely as a reporter assayin an animal cultured cell system at present. Renilla luciferase having311 amino acids is used for a reporter assay inside of cells. For anextracellular reporter assay, the secretory Gaussia luciferase having168 amino acids is used. Comparison in specific activity betweenrecombinant Renilla luciferase and recombinant Gaussia luciferase usingcoelenterazine as a substrate reveals that the specific activity ofRenilla luciferase is about 1/100 of Gaussia luciferase (Non-PatentDocuments 5 and 6). On the other hand, the specific activity of themutated 19 kDa protein which catalyzes the luminescence reaction is 1/10of Gaussia luciferase and the mutated 19 kDa protein was found to beobviously inferior as a reporter assay gene as a secretory protein bycomparison with Gaussia luciferase.

In view of the foregoing, there has been desired a reporter gene that isa luciferase expressed intracellularly and exhibits higher luminescenceactivity than wild 19 kDa protein, when not only coelenterazine but itsanalogue is used as a substrate.

RELATED ART DOCUMENTS Patent Documents

-   [Patent Document 1] Japanese Patent No. 4613441-   [Patent Document 2] Japanese National Publication (Tokuhyo) No.    2012-525819

Non-Patent Documents

-   [Non-Patent Document 1] O. Shimomura et al. (1978) Biochemistry 17:    994-998.-   [Non-Patent Document 2] S. Inouye et al. (2000) FEBS Lett. 481:    19-25.-   [Non-Patent Document 3] S. Inouye & S. Sasaki (2007) Protein    Express. Purif. 56: 261-268.-   [Non-Patent Document 4] M. P. Hall et al. (2012) ACS Chem. Biol. 7:    1848-1857.-   [Non-Patent Document 5] S. Inouye et al. (2013) Biochem. Biophys.    Res. Commun. 437: 23-28.-   [Non-Patent Document 6] S. Inouye et al. (2013) Protein Express.    Purif. 88: 150-156.

DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention

Under the foregoing circumstances, a novel luciferase that is distinctfrom conventional luciferases has been desired.

Means for Solving the Problem

The present inventors have made extensive investigations to solve theproblem above and examined all of the mutated positions in the knownmutated 19 kDa protein which catalyzes luminescence reaction. As aresult, the inventors have newly produced the luciferase mutants by themethod of selection and combination of the mutations, which have higheractivity than the known mutated 19 kDa protein having catalytic activityof luminescence and are hardly secreted extracellularly when expressedin animal cultured cells. The present invention has thus beenaccomplished.

More specifically, the present invention provides the followingluciferase mutants, polynucleotides, recombinant vectors, transformants,a method of producing luciferase mutants, kits, a method of performing aluminescence reaction, and so on.

[1] A luciferase mutant defined in (a) or (b) below:

(a) a luciferase mutant comprising an amino acid sequence in which atleast one amino acid selected from the group consisting of valine at theposition of 44, alanine at the position of 54 and tyrosine at theposition of 138 is substituted with other amino acid(s) in the aminoacid sequence of SEQ ID NO: 2; or,

(b) a luciferase mutant comprising an amino acid sequence in which atleast one amino acid selected from the group consisting of valine at theposition of 44, alanine at the position of 54 and tyrosine at theposition of 138 is substituted with other amino acid(s) and one or moreamino acids are substituted with other amino acid(s) at position(s)except for the positions of 4, 11, 18, 27, 33, 43, 68, 72, 75, 90, 115,124 and 166 in the amino acid sequence of SEQ ID NO: 2, and havingluciferase activity.

[2] The luciferase mutant according to [1] above, wherein saidluciferase mutant defined in (b) above is (c) below:

(c) a luciferase mutant comprising an amino acid sequence of SEQ ID NO.2 in which at least one amino acid selected from the group consisting ofvaline at the position of 44, alanine at the position of 54 and tyrosineat the position of 138 is substituted with other amino acid(s) and 1 to16 amino acids is/are substituted with other amino acid(s) atposition(s) except for the positions of 4, 11, 18, 27, 33, 43, 68, 72,75, 90, 115, 124 and 166, and having luciferase activity

[3] The luciferase mutant according to [1] or [2] above, wherein theother amino acid(s) which is/are substituted for at least one amino acidselected from the group consisting of valine at the position of 44,alanine at the position of 54 and tyrosine at the position of 138 is/areisoleucine.

[4] The luciferase mutant according to [1] above, wherein the proteindefined in (a) above comprises an amino acid sequence of SEQ ID NO: 16,SEQ ID NO: 14, SEQ ID NO: 12, SEQ ID NO: 10, SEQ ID NO: 8, SEQ ID NO: 6or SEQ ID NO: 4.

[5] A polynucleotide comprising a polynucleotide encoding the luciferasemutant according to any one of [1] to [4] above.

[6] A recombinant vector comprising the polynucleotide according to [5]above.

[7] A transformant transformed with the recombinant vector according to[6] above.

[8] A method of producing the luciferase mutant according to any one of[1] to [4] above, which comprises the steps of culturing thetransformant of [7] above and producing the luciferase mutant accordingto any one of [1] to [4] above.

[9] A kit comprising at least one selected from the luciferase mutantaccording to any one of [1] to [4] above, the polynucleotide accordingto [5] above, the recombinant vector according to [6] above and thetransformant according to [7] above.

[10] The kit according to [9] above, further comprising a luciferin.

[11] The kit according to [10] above, wherein the luciferin iscoelenterazines.

[12] The kit according to [11] above, wherein the coelenterazines iscoelenterazine.

[13] A method for performing a luminescence reaction, which comprisescontacting the luciferase mutant according to any one of [1] to [4]above with a luciferin.

[14] The method according to [13] above, wherein the luciferin iscoelenterazines.

[15] The method according to [14] above, wherein the coelenterazines iscoelenterazine.

[16] A method for assaying activity of a sequence associated with theregulation of a promoter, which comprises using the polynucleotideaccording to [5] above as a reporter gene and contacting a luciferasemutant encoded by the reporter gene with a luciferin.

[17] The method according to [16] above, wherein the luciferin iscoelenterazines.

[18] The method according to [17] above, wherein the coelenterazines iscoelenterazine.

Effects of the Invention

The present invention provides luciferase mutants that are differentfrom the known ones. In a preferred embodiment of the invention, theluciferase mutants have at least one property selected from theproperties having higher luminescence activity than that of native 19kDa protein and/or the known mutated 19 kDa protein capable ofcatalyzing luminescence reaction when coelenterazine and its analogueswere used as a substrate, and little extracellular secretion whenexpressed in animal cells, and so on.

BRIEF DESCRIPTION OF DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawing(s) will be provided by the Office upon request and paymentof the necessary fee.

FIG. 1 shows the results of SDS-PAGE analysis of the supernatant andprecipitate fractions from the crude enzyme solution (crude extract) ofE. coli in which the KAZ mutants were expressed using pCold II vector.

FIG. 2 shows the results of SDS-PAGE analysis of the crude enzymesolution of E. coli in which the KAZ mutants were expressed usingpCold-ZZ-P vector.

FIG. 3 shows the results of SDS-PAGE analysis of the supernatant andprecipitate fractions from the crude enzyme solution of E. coli in whichthe KAZ mutants were expressed using pCold II vector.

FIG. 4 shows the results of SDS-PAGE analysis of the crude enzymesolution of E. coli in which the KAZ mutants were expressed usingpCold-ZZ-P vector.

MODE FOR CARRYING OUT THE INVENTION

The present invention will be described below in detail.

1. Luciferase Mutants of the Invention

The term luciferase mutant in the present invention refers to a mutantof the protein with a molecular weight of 19 kDa of Oplophorusluciferase. Specifically, the luciferase mutant of the present inventionis intended to mean a luciferase mutant having substantially the sameactivity as the luciferase mutant comprising an amino acid sequence inwhich at least one amino acid selected from the group consisting ofvaline at the position of 44, alanine at the position of 54 and tyrosineat the position of 138 in the amino acid sequence of SEQ ID NO: 2 issubstituted with other amino acid(s).

The term substantially the same activity is intended to mean at leastone activity selected from luciferase activity, activity with littleextracellular secretion when expressed in animal cells, and so on.

The term “luciferase activity” is intended to mean the activity forcatalyzing the luminescence reaction using a luciferin (e.g.,coelenterazines) which serves as a substrate, namely, the reaction inwhich luciferin (e.g., coelenterazines) is oxidized with molecularoxygen to produce oxyluciferin in its excited state. The excited stateof oxyluciferin produced emits visible light and converts to the groundstate.

Luminescence activity can be determined by the method described in,e.g., Inouye, S. & Shimomura, O. (1977) Biochem. Biophys. Res. Commun.233, 349-353. Specifically, the luciferase mutant of the presentinvention is mixed with a luciferin to start the luminescence reaction,and the activity of catalyzing luminescence reaction can be determinedusing a luminometer. Commercially available luminometers, e.g.,Luminescencer-PSN AB2200 (manufactured by Atto Corp.) or Centro 960Luminometer (manufactured by Berthold Inc.) may be used as luminometers.

The luciferin used in the present invention may be any luciferin as faras it serves as a substrate for the luciferase mutants of the presentinvention. Specifically, the luciferin used in the present inventionincludes coelenterazines containing the imidazopyrazinone ring as thebackbone.

The term coelenterazines are used to mean coelenterazine or itsanalogues. Coelenterazine analogues include, for example,bis-coelenterazine, deoxyfuran-coelenterazine (furimazine)),h-coelenterazine, hcp-coelenterazine, cp-coelenterazine,f-coelenterazine, fcp-coelenterazine, n-coelenterazine,MeO-coelenterazine, e-coelenterazine, cl-coelenterazine,ch-coelenterazine, 3iso-coelenterazine, 3meo-coelenterazine,cf3-coelenterazine, i-coelenterazine, et-coelenterazine,me-coelenterazine, 3me-coelenterazine, ameh-coelenterazine,8-(1-naphthyl)-coelenterazine, 8-(2-naphthyl)-coelenterazine,8-(2-thienyl)-coelenterazine, 6,8-di-(2-thienyl)-coelenterazine,8-(4-hydroxyphenyl)-coelenterazine, 8-(2-benzothienyl)-coelenterazine,8-(b-styryl)-coelenterazine, 8-phenyl-coelenterazine,6-deoxy-coelenterazine, 8-(3-thienyl)-coelenterazine, and8-(3-benzo[b]thienyl)-coelenterazine. Of these coelenterazines,coelenterazine is particularly preferred in the present invention.

These coelenterazines may be synthesized by publicly known methods ormay also be commercially available.

The coelenterazines may be synthesized by the methods described in,e.g., Shimomura et al. (1988) Biochem. J. 251, 405-410, Shimomura et al.(1989) Biochem. J. 261, 913-920, Shimomura et al. (1990) Biochem. J.270, 309-312, Tetrahedron Lett. 38: 6405-6406, WO 2010/090319, or Inouyeet al. (2010) Anal. Biochem. 407, 247-252, or respective modificationsthereof. Furimazine may be produced by the method described in Hall etal. (2012) ACS Chem. Biol. 16; 848-1857.

The coelenterazines which are commercially available include, forexample, coelenterazine, cf3-coelenterazine and h-coelenterazinemanufactured by JNC Corp.; hcp-coelenterazine, cp-coelenterazine,f-coelenterazine, fcp-coelenterazine and n-coelenterazine manufacturedby Biotium Inc.; and coelenterazine, furimazine and h-coelenterazinemanufactured by Promega Corp.

The “activity for catalyzing luminescence reaction using a luciferinwhich serves as a substrate” is activity for catalyzing luminescencereaction preferably using coelenterazines whish serves as a substrate.The “activity for catalyzing luminescence using coelenterazines as asubstrate” is activity for catalyzing luminescence reaction preferablyusing coelenterazine which serves as a substrate.

The “activity with little extracellular secretion when expressed inanimal cells” is intended to mean that when expressed in animal cells, alarge part of the expressed protein is not transported but retained inthe cells and hardly secreted outside the cells. Specifically, the“hardly secreted outside of cells” is intended to mean that theexpressed protein is secreted outside the cells only in a trace amount(weight) of less than 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, 0.01% or0.005%. The “animal cells” include those later described.

The “luciferase mutant having substantially the same activity as theluciferase mutant comprising an amino acid sequence in which at leastone amino acid selected from the group consisting of valine at theposition of 44, alanine at the position of 54 and tyrosine at theposition of 138 in the amino acid sequence of SEQ ID NO: 2 issubstituted with other amino acid(s)” is, for example, the luciferasemutant described (a) or (b) below.

(a) A luciferase mutant comprising an amino acid sequence in which atleast one amino acid selected from the group consisting of valine at theposition of 44, alanine at the position of 54 and tyrosine at theposition of 138 is substituted with different (or other) amino acid(s)in the amino acid sequence of SEQ ID NO: 2;

(b) a luciferase mutant comprising an amino acid sequence in which atleast one amino acid selected from the group consisting of valine at theposition of 44, alanine at the position of 54 and tyrosine at theposition of 138 is substituted with other amino acid(s) and one or moreamino acids are substituted with other amino acid(s) at position(s)except for the positions of 4, 11, 18, 27, 33, 43, 68, 72, 75, 90, 115,124 and 166 in the amino acid sequence of SEQ ID NO: 2, and havingluciferase activity.

In (a) and (b) above, the term “at least one amino acid is substitutedwith other amino acid(s)” is intended to mean a substitution of at leastone amino acid at 1 to 3 position(s) selected from the positions of 44,54 and 138 in the amino acid sequence of SEQ ID NO: 2.

Specifically, “at least one” in “at least one amino acid is substitutedwith other amino acid(s)” is 1, 2 or 3, preferably 2 or 3, and morepreferably 3.

The other amino acid which is substituted for valine at the position of44 in the amino acid sequence of SEQ ID NO: 2 includes, for example,isoleucine, alanine, methionine, leucine, cysteine, serine andphenylalanine, preferably, isoleucine, alanine, methionine, leucine andcysteine, and more preferably, isoleucine.

The other amino acid which is substituted for alanine at the position of54 in the amino acid sequence of SEQ ID NO: 2 is, for example,isoleucine, valine, methionine, leucine, cysteine, serine orphenylalanine, preferably, isoleucine, valine, methionine, leucine orcysteine, and more preferably, isoleucine.

The other amino acid which is substituted for tyrosine at the positionof 138 in the amino acid sequence of SEQ ID NO: 2 is, for example,isoleucine, valine, leucine, methionine, cysteine, threonine, arginine,lysine, histidine or glutamine, preferably, isoleucine, valine, leucine,methionine, arginine or lysine, and more preferably, isoleucine.

The other amino acid(s) which is/are substituted for at least one aminoacid selected from the group consisting of valine at the position of 44,alanine at the position of 54 and tyrosine at the position of 138 in theamino acid sequence of SEQ ID NO: 2 is/are preferably isoleucine.

In (b) above, the term “one or more amino acids are substituted withother amino acid(s)” is intended to mean that one or more substitutionsoccur at optional and one or more positions in the same amino acidsequence.

The range of “one or more” in “one or more amino acids are substitutedwith other amino acids” is, for example, 1 to 35, 1 to 34, 1 to 33, 1 to32, 1 to 31, 1 to 30, 1 to 29, 1 to 28, 1 to 27, 1 to 26, 1 to 25, 1 to24, 1 to 23, 1 to 22, 1 to 21, 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to8, 1 to 7, 1 to 6 (1 to several), 1 to 5, 1 to 4, 1 to 3, 1 to 2 and 1.In general, the less the number of amino acids substituted, the morepreferable. Such proteins may be produced by site-directed mutagenesisdescribed in “Sambrook J. et al., Molecular Cloning: A LaboratoryManual, Third Edition, Cold Spring Harbor Laboratory Press (2001),”“Ausbel F. M. et al., Current Protocols in Molecular Biology, Supplement1-38, John Wiley and Sons (1987-1997),” “Nuc. Acids. Res., 10, 6487(1982),” “Proc. Natl. Acad. Sci. USA, 79, 6409 (1982),” “Gene, 34, 315(1985),” “Nuc. Acids. Res., 13, 4431 (1985),” or “Proc. Natl. Acad. Sci.USA, 82, 488 (1985),” etc.

The position(s) of the amino acid(s) which is/are substituted in theamino acid sequence of SEQ ID NO: 2 is/are not particularly limited solong as the position(s) is/are other than the positions of 4, 11, 18,27, 33, 43, 68, 72, 75, 90, 115, 124 and 166, in addition to thesubstitution positions of 44, 54 and 138 described above, and includeone or more positions selected from the group consisting of thepositions of 1, 2, 3, 13, 14, 15, 25, 30, 36, 70, 83, 106, 128, 153,156, 157, 159, 162, 163 and 169, preferably, position(s) selected fromthe group consisting of the positions of 1, 2, 3, 13, 14, 153, 159, 163and 169.

Examples of amino acid residues which are mutually substitutable aregiven below. Amino acid residues in the same group are mutuallysubstitutable.

Group A: leucine, isoleucine, norleucine, valine, norvaline, alanine,2-aminobutanoic acid, methionine, o-methylserine, t-butylglycine,t-butylalanine and cyclohexylalanine;Group B: aspartic acid, glutamic acid, isoaspartic acid, isoglutamicacid, 2-aminoadipic acid and 2-aminosuberic acid;Group C: asparagine and glutamine;Group D: lysine, arginine, ornithine, 2,4-diaminobutanoic acid and2,3-diaminopropionic acid;Group E: proline, 3-hydroxyproline and 4-hydroxyproline;Group F: serine, threonine and homoserine; and,Group G: phenylalanine and tyrosine.

In a preferred embodiment of the invention, the luciferase mutant is aluciferase mutant comprising the amino acid sequence of SEQ ID NO: 16,SEQ ID NO: 14, SEQ ID NO: 12, SEQ ID NO: 10, SEQ ID NO: 8, SEQ ID NO: 6or SEQ ID NO: 4, more preferably, a luciferase mutant comprising theamino acid sequence of SEQ ID NO: 16, SEQ ID NO: 14, SEQ ID NO: 12 orSEQ ID NO: 10, and most preferably, a luciferase mutant comprising theamino acid sequence of SEQ ID NO: 16.

The luciferase mutant of the present invention may further contain anadditional peptide sequence at the N terminus and/or C terminus,preferably at the N terminus. The additional peptide sequence is atleast one peptide sequence selected from the group consisting of apeptide sequence for purification, a peptide sequence for expressing theluciferase mutant of the present invention as a soluble protein and anepitope sequence capable of recognizing an antibody. The additionalpeptide sequence is preferably a peptide sequence for purification. Inanother preferred embodiment of the present invention, the additionalpeptide sequence is at least one sequence selected from the groupconsisting of a peptide sequence for purification and a peptide sequencefor expressing the luciferase mutant of the present invention as asoluble protein.

Peptide sequences employed in the art may be used as the peptidesequence for purification. The peptide sequence for purificationincludes, for example, a histidine tag sequence having a consecutiveamino acid sequence of at least 4 and preferably at least 6 histidineresidues, an amino acid sequence with a binding domain of glutathioneS-transferase into glutathione, the amino acid sequence of Protein A,etc.

The peptide used to express the luciferase mutant of the presentinvention as a soluble protein includes, for example, polypeptidesrepresented by formula (Z)n. The amino acid sequences for thepolypeptides represented by formula (Z)n and the nucleic acid sequencesencoding the same are described in, e.g., JPA KOKAI No. 2008-99669.

Peptide sequences used in the art can be used as the epitope sequencecapable of recognizing an antibody.

The method for acquiring the luciferase mutant of the invention is notparticularly limited. The luciferase mutant of the invention may be aprotein synthesized by chemical synthesis, or a recombinant proteinproduced by a genetic engineering technique. When the luciferase mutantof the invention is to be chemically synthesized, synthesis may becarried out by, for example, the Fmoc (fluorenylmethyloxycarbonyl)method or the tBoc (t-butyloxycarbonyl) method. In addition, peptidesynthesizers available from Advanced ChemTech, PerkinElmer, Pharmacia,Protein Technology Instrument, Synthecell-Vega, PerSeptive, ShimadzuCorporation, etc. may also be used for chemical synthesis. When theluciferase mutant of the invention is to be produced by geneticengineering, the mutant may be produced by a conventional geneticrecombination technique. More specifically, the luciferase mutant of theinvention may be produced by inserting a polynucleotide (e.g., a DNA)encoding the luciferase mutant of the invention into a suitableexpression system. The polynucleotide encoding the luciferase mutant ofthe invention, expression of the luciferase mutant of the invention inan expression system or the like will be later described.

2. Polynucleotide of the Invention

The present invention also provides a polynucleotide comprising apolynucleotide encoding the luciferase mutant of the invention describedabove. The polynucleotide of the invention may be any polynucleotide solong as it has a nucleotide sequence encoding the luciferase mutant ofthe invention, although a DNA is preferred. Examples of the DNA includegenomic DNA, genomic DNA library, cellular or tissue cDNA, cellular ortissue cDNA library, synthetic DNA, etc. Vectors used in the librariesare not particularly limited and may be any of bacteriophages, plasmids,cosmids, phagemids, etc. Also, these vectors may be amplified directlyby a Reverse Transcription Polymerase Chain Reaction (hereinafterabbreviated as RT-PCR) using the total RNA or mRNA fraction preparedfrom the cell or tissue described above.

The polynucleotide of the invention includes the followingpolynucleotides.

(i) A polynucleotide comprising a polynucleotide encoding the luciferasemutant comprising an amino acid sequence in which at least one aminoacid selected from the group consisting of valine at the position of 44,alanine at the position of 54 and tyrosine at the position of 138 issubstituted with other amino acid(s) in the amino acid sequence of SEQID NO: 2; or,

(ii) A polynucleotide comprising a polynucleotide encoding theluciferase mutant comprising an amino acid sequence in which at leastone amino acid selected from the group consisting of valine at theposition of 44, alanine at the position of 54 and tyrosine at theposition of 138 is substituted with other amino acid(s) and one or moreamino acids are substituted with other amino acid(s) at position(s)except for the positions of 4, 11, 18, 27, 33, 43, 68, 72, 75, 90, 115,124 and 166 in the amino acid sequence of SEQ ID NO: 2, and havingluciferase activity.

The luciferase mutants of (i) and (ii) above are as described above.

A polynucleotide encoding a protein having a given amino acid sequence,in which one or more amino acids are substituted in the amino acidsequence, can be obtained by using a site-specific mutagenesis technique(see, e.g., Gotoh, T. et al., Gene 152, 271-275 (1995), Zoller, M. J.,and Smith, M., Methods Enzymol. 100, 468-500 (1983), Kramer, W. et al.,Nucleic Acids Res. 12, 9441-9456 (1984), Kramer W, and Fritz H. J.,Methods. Enzymol. 154, 350-367 (1987), Kunkel, T. A., Proc. Natl. Acad.Sci. USA. 82, 488-492 (1985), Kunkel, Methods Enzymol. 85, 2763-2766(1988); etc.), the methods using amber mutation (see, e.g., the gappedduplex method, Nucleic Acids Res., 12, 9441-9456 (1984), etc.), etc.

Alternatively, mutations can also be introduced into the polynucleotideby PCR (cf., e.g., Ho S. N. et al., Gene, 77, 51 (1989), etc.) using apair of primers bearing on the respective 5′ ends a sequence in whichthe targeted mutation (deletion, addition, substitution and/orinsertion) has been introduced.

Also, a polynucleotide encoding a partial fragment of protein, which isone type of deletion mutant, can be obtained using as the primers anoligonucleotide having a sequence which matches the nucleotide sequenceat the 5′ end of the region encoding the partial fragment to be producedin the polynucleotide encoding the target protein and an oligonucleotidehaving a sequence complementary to the nucleotide sequence at the 3′ endthereof, and performing PCR in which the polynucleotide encoding thetarget protein is used as a template.

The polynucleotide of the present invention includes preferably apolynucleotide comprising a polynucleotide encoding the luciferasemutant comprising the amino acid sequence of SEQ ID NO: 16, SEQ ID NO:14, SEQ ID NO: 12, SEQ ID NO: 10, SEQ ID NO: 8, SEQ ID NO: 6 or SEQ IDNO: 4, more preferably, a polynucleotide comprising a polynucleotideencoding the luciferase mutant comprising the amino acid sequence of SEQID NO: 16, SEQ ID NO: 14, SEQ ID NO: 12 or SEQ ID NO: 10, and mostpreferably, a polynucleotide comprising a polynucleotide encoding theluciferase mutant comprising the amino acid sequence of SEQ ID NO: 16.

The polynucleotide encoding the luciferase mutant comprising the aminoacid sequence of SEQ ID NO: 16 includes a polynucleotide comprising thenucleotide sequence of SEQ ID NO: 15. The polynucleotide encoding theluciferase mutant comprising the amino acid sequence of SEQ ID NO: 14includes a polynucleotide comprising the nucleotide sequence of SEQ IDNO: 13. The polynucleotide encoding the luciferase mutant comprising theamino acid sequence of SEQ ID NO: 12 includes a polynucleotidecomprising the nucleotide sequence of SEQ ID NO: 11. The polynucleotideencoding the luciferase mutant comprising the amino acid sequence of SEQID NO: 10 includes a polynucleotide comprising the nucleotide sequenceof SEQ ID NO: 9. The polynucleotide encoding the luciferase mutantcomprising the amino acid sequence of SEQ ID NO: 8 includes apolynucleotide comprising the nucleotide sequence of SEQ ID NO: 7. Thepolynucleotide encoding the luciferase mutant comprising the amino acidsequence of SEQ ID NO: 6 includes a polynucleotide comprising thenucleotide sequence of SEQ ID NO: 5. The polynucleotide encoding theluciferase mutant comprising the amino acid sequence of SEQ ID NO: 4includes a polynucleotide comprising the nucleotide sequence of SEQ IDNO: 3.

In some embodiments of the present invention, the polynucleotide ispreferably a polynucleotide comprising a polynucleotide consisting ofthe nucleotide sequence of SEQ ID NO: 15, SEQ ID NO: 13, SEQ ID NO: 11,SEQ ID NO: 9, SEQ ID NO: 7, SEQ ID NO: 5 or SEQ ID NO: 3, morepreferably, a polynucleotide comprising a polynucleotide consisting ofthe nucleotide sequence of SEQ ID NO: 15, SEQ ID NO: 13, SEQ ID NO: 11or SEQ ID NO: 9, and most preferably, a polynucleotide comprising apolynucleotide consisting of the nucleotide sequence of SEQ ID NO: 15.

The polynucleotide of the present invention may further contain apolynucleotide encoding an additional peptide sequence at the 5′ endand/or 3′ end, preferably at the 5′ end. The polynucleotide encodingsuch an additional peptide sequence includes a polynucleotide encodingat least one peptide sequence selected from the group consisting of apeptide sequence for purification, a peptide sequence for expressing theluciferase mutant of the present invention as a soluble protein, anepitope sequence capable of recognizing an antibody, and the like.

Polynucleotides comprising nucleotide sequences encoding the peptidesequence for purification employed in the art can be used as thepolynucleotide encoding the peptide sequence for purification. Examplesof the peptide sequence for purification include those as describedabove.

The polynucleotide encoding the peptide sequence used to express theluciferase mutant of the present invention as a soluble proteinincludes, for example, polypeptides represented by formula (Z)n. Theamino acid sequences for the polypeptides represented by formula (Z)nand the nucleic acid sequences encoding the same are those as describedabove.

Polynucleotides comprising nucleotide sequences encoding the epitopesequence capable of recognizing antibodies that are used in the art canbe used as the polynucleotide encoding the antibody-recognizing epitopesequence.

3. Recombinant Vector and Transformant of the Invention

The present invention further provides recombinant vectors andtransformants comprising the polynucleotides of the present inventiondescribed above.

Preparation of Recombinant Vector

The recombinant vector of the invention can be obtained by ligating(inserting) the polynucleotide (DNA) of the invention to (into) anappropriate vector. Specifically, the recombinant vector can be obtainedby digesting the purified polynucleotide (DNA) with a suitablerestriction enzyme, then inserting into a suitable vector at therestriction enzyme site or multicloning site, and ligating to thevector. The vector for inserting the polynucleotide of the invention isnot particularly limited as long as it is replicable in a host, andincludes plasmids, bacteriophages, animal viruses, etc. Examples ofplasmids include plasmids from E. coli (e.g., pBR322, pBR325, pUC118,pUC119, etc.), plasmids from Bacillus subtilis (e.g., pUB110, pTP5,etc.) and plasmids from yeast (e.g., YEp13, YEp24, YCp50, etc.).Examples of bacteriophages include, e.g., X phage. Examples of animalviruses include retroviruses, vaccinia viruses and insect viruses (e.g.,baculoviruses). In addition, pCold I vector, pCold II vector, pCold IIIvector and pCold IV vector (all are manufactured by Takara Bio Inc.),pcDNA3 vector, PICZ vector (manufactured by Invitrogen Inc.) and thelike may also be suitably used.

The polynucleotide of the present invention is generally ligateddownstream to a promoter in a suitable vector in an expressible manner.When the host used for transformation is an animal cell, the promoter ispreferably an SV40-derived promoter, retrovirus promoter,metallothionein promoter, heat shock promoter, cytomegalovirus promoter,SRα promoter, and so on. When the host is a bacterium of the genusEscherichia, Trp promoter, T7 promoter, lac promoter, recA promoter, λPLpromoter, 1pp promoter, etc. are preferred. When the host is a bacteriumof the genus Bacillus, SPO1 promoter, SPO2 promoter, penP promoter, etc.are preferred. When the host is yeast, PHOS promoter, PGK promoter, GAPpromoter, ADH1 promoter, GAL promoter, etc. are preferred. When the hostis an insect cell, polyhedrin promoter, P10 promoter, etc. arepreferred.

A low-temperature expression-inducible promoter may also be suitablyused. Examples of the low-temperature expression-inducible promoterinclude promoter sequences for cold shock genes. The cold shock geneincludes, for example, E. coli cold shock genes (e.g., cspA, cspB, cspG,cspI and csdA), Bacillus caldolyticus cold shock genes (e.g., Bc-Csp),Salmonella enterica cold shock genes (e.g., cspE) and Erwinia carotovoracold shock genes (e.g., cspG). Among others, cspA promoter, cspBpromoter, cspG promoter, cspI promoter, csdA promoter and the like canbe advantageously used as the low-temperature expression-induciblepromoter.

In addition to the foregoing, the recombinant vector of the inventionmay further contain, if desired, an enhancer, a splicing signal, a polyAaddition signal, a ribosome binding sequence (SD sequence), a selectionmarker, etc., and provided for use. The selection marker includes, forexample, a dihydrofolate reductase gene, an ampicillin resistance gene,a neomycin resistance gene, etc.

Preparation of Transformant

The thus obtained recombinant vector comprising the polynucleotide ofthe invention is introduced into an appropriate host to prepare thetransformant. The host is not particularly limited as long as it iscapable of expressing the polynucleotide (DNA) of the invention, and maybe bacteria of the genera Escherichia, Bacillus, Pseudomonas andRhizobium, yeast, animal cells or insect cells, etc. Bacteria of thegenus Escherichia include E. coli, etc. Bacteria of the genus Bacillusinclude Bacillus subtilis, etc. Bacteria of the genus Pseudomonasinclude Pseudomonas putida, etc. Bacteria of the genus Rhizobium includeRhizobium meliloti, etc. Yeast includes Saccharomyces cerevisiae,Schizosaccharomyces pombe, etc. Animal cells include COS cells, CHOcells, HeLa cells, etc. Insect cells include Sf9, Sf21, etc.

The method of transfecting the recombinant vector into the host and themethod of transformation by the same can be performed according tovarious general methods. The method for transfecting the recombinantvector into the host cell includes the calcium phosphate method(Virology, 52, 456-457 (1973)), the lipofection method (Proc. Natl.Acad. Sci. USA, 84, 7413 (1987)), the electroporation method (EMBO J.,1, 841-845 (1982)), etc. The method for transformation of the bacteriaof the genus Escherichia includes the methods described in, e.g., Proc.Natl. Acad. Sci. USA, 69, 2110 (1972), Gene, 17, 107 (1982), etc. Themethod for transformation of the bacteria of the genus Bacillus includesthe method described in Molecular & General Genetics, 168, 111 (1979),etc. The method for transforming yeast includes the method described inProc. Natl. Acad. Sci. USA, 75, 1929 (1978), etc. The method fortransformation of animal cells includes the method described inVirology, 52, 456 (1973), etc. The method for transformation of insectcells includes the method described in Bio/Technology, 6, 47-55 (1988),etc. Thus, the transformant transformed with the recombinant vectorcomprising the polynucleotide encoding the luciferase mutant of theinvention (the polynucleotide of the invention) can be obtained.

Expression Vector and Transformant Comprising Low-TemperatureExpression-Inducible Promoter Sequence

An expression vector comprising the low-temperature expression-induciblepromoter sequence is preferred as the expression vector among others.

Specifically, the expression vector comprising the low-temperatureexpression-inducible promoter sequence is intended to mean an expressionvector comprising the following promoter sequence and coding sequence:

(1) a low-temperature expression-inducible promoter sequence; and,(2) a coding sequence comprising the polynucleotide of the invention.

The low-temperature expression-inducible promoter sequence is intendedto mean a promoter sequence which is capable of inducing expression ofthe protein by lowering the temperature from the culture conditionsunder which host cells can grow. Examples of the low-temperatureexpression-inducible promoter are promoters for genes encoding coldshock proteins (cold shock genes). Examples of the cold shock genepromoters include those as described above.

The temperature at which the low-temperature expression-induciblepromoter used in the invention can induce expression is generally 30° C.or less, preferably 25° C. or less, more preferably 20° C. or less, andmost preferably 15° C. or less. In order to induce the expression moreefficiently, however, the expression induction is generally performed at5° C. or more, preferably at 10° C. or more, and most preferably atapproximately 15° C.

In preparing the expression vector of the invention comprising thelow-temperature expression-inducible promoter sequence, the pCold Ivector, pCold II vector, pCold III vector, and pCold IV vector (allmanufactured by Takara Bio Inc.) can be suitably used as the vector forinsertion of the polynucleotide of the invention. The protein can beproduced as a soluble protein in the cytoplasm in a host cell whenexpressed in a prokaryotic host cell using these vectors.

Prokaryotic cells are preferred as the host into which the expressionvector comprising the low-temperature expression-inducible promotersequence is introduced, more preferably, E. coli, and particularlypreferably, the BL21 and JM109 strains. Among others, the BL21 strain ismost preferred.

Temperatures for incubation at which the transformant carrying theexpression vector comprising the low-temperature expression-induciblepromoter sequence grows are generally 25 to 40° C. and preferably 30 to37° C. Temperatures for inducing the expression are generally 4 to 25°C., preferably 10 to 20° C., more preferably 12 to 18° C., and mostpreferably 15° C.

4. Production of Luciferase Mutant of the Invention

The present invention further provides a method for producing theluciferase mutant of the invention, which comprises the steps ofculturing the transformant described above to produce the luciferasemutant of the invention. The luciferase mutant of the invention can beproduced, for example, by culturing the transformant described aboveunder conditions where the polynucleotide (DNA) encoding the luciferasemutant of the invention can be expressed, producing/accumulating andthen separating/purifying the luciferase mutant of the invention.

Incubation of Transformant

The transformant of the invention may be incubated in a conventionalmanner used for incubation of a host. By the incubation, the luciferasemutant of the invention is produced from the transformant andaccumulated in the transformant or in the culture medium.

The medium used for culturing the transformant using bacteria of thegenus Escherichia or the genus Bacillus as a host may be any of anatural medium and a synthetic medium as far as it is a medium whichcontains carbon sources, nitrogen sources, inorganic salts, etc.necessary for growth of the transformant, and in which the transformantcan efficiently grow. Examples of carbon sources which can be used arecarbohydrates such as glucose, fructose, sucrose, starch, etc.; organicacids such as acetic acid, propionic acid, etc.; alcohols such asethanol, propanol, and the like. Examples of nitrogen sources which canbe used include ammonia, ammonium salts of inorganic or organic acidssuch as ammonium chloride, ammonium sulfate, ammonium acetate, ammoniumphosphate, etc., and other nitrogen-containing compounds, and furtherinclude peptone, meat extracts, corn steep liquor, and the like.Examples of inorganic salts include monobasic potassium phosphate,dibasic potassium phosphate, magnesium phosphate, magnesium sulfate,sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate,calcium carbonate, etc. If necessary, antibiotics such as ampicillin ortetracycline can be added to the medium during incubation. Where thetransformant transformed by the expression vector using an induciblepromoter as the promoter is cultured, an inducer may also be added tothe medium, if necessary. For example, when the transformant transformedby an expression vector using a lac promoter is cultured,isopropyl-β-D-thiogalactopyranoside (IPTG), etc. may be added to themedium and indoleacrylic acid (IAA), etc. may be added to the medium inculturing the transformant transformed by an expression vector using atrp promoter.

When the host is bacteria of the genus Escherichia, incubation isperformed generally at approximately 15 to 43° C. for approximately 3 to24 hours. If necessary, aeration and agitation may be applied. When thehost is bacteria of the genus Bacillus, incubation is performedgenerally at approximately 30 to 40° C. for approximately 6 to 24 hours.If necessary, aeration and agitation may be applied.

Media for incubation of the transformant when the host is yeast includeBurkholder's minimal medium (Proc. Natl. Acad. Sci. USA, 77, 4505(1980)) and an SD medium containing 0.5% (w/v) Casamino acids (Proc.Natl. Acad. Sci. USA, 81, 5330 (1984)). Preferably, the pH of the mediumis adjusted to approximately 5 to 8. Incubation is performed generallyat approximately 20 to 35° C. for approximately 24 to 72 hours. Ifnecessary, aeration and agitation may be applied.

Media for culturing the transformant when the host is an animal cellinclude MEM medium supplemented with approximately 5 to 20% (v/v) fetalcalf serum (Science, 122, 501 (1952)), DMEM medium (Virology, 8, 396(1959)), etc. Preferably, the pH of the medium is adjusted toapproximately 6 to 8. Incubation is performed generally at approximately30 to 40° C. for approximately 15 to 60 hours. If necessary, aerationand agitation may be applied.

Media for culturing the transformant when the host is an insect cellinclude Grace's insect medium (Nature, 195, 788 (1962)) to whichadditives such as 10% (v/v) immobilized bovine serum are suitably added.Preferably, the pH of the medium is adjusted to approximately 6.2 to6.4. Incubation is performed generally at approximately 27° C. forapproximately 3 to 5 days. If necessary, aeration and agitation may beapplied.

Temperatures for incubation at which the transformant transformed by theexpression vector comprising the low-temperature expression-induciblepromoter sequence and temperatures for expression induction are asdescribed above.

Separation/Purification of Luciferase Mutant of the Invention

The luciferase mutant of the invention can be obtained byseparating/purifying the luciferase mutant of the invention from theculture described above. As used herein, the culture is intended to meanany one of a culture broth, cultured cells or cultured bacteria and acell lysate of the cultured cells or cultured bacteria. The luciferasemutant of the invention can be separated/purified in a conventionalmanner.

Specifically, when the luciferase mutant of the invention accumulates inthe cultured bacteria or cultured cells, after completion of theincubation the bacteria or cells are disrupted in a conventional manner(e.g., ultrasonication, lysozyme, freezing and thawing, etc,) and then acrude extract of the luciferase mutant of the invention can be obtainedin a conventional manner (e.g., centrifugation, filtration, etc.). Whenthe luciferase mutant of the invention accumulates in the periplasmicspace, after completion of the incubation the extract containing theluciferase mutant of the invention can be obtained in a conventionalmanner (e.g., the osmotic shock method, etc.). When the luciferasemutant of the invention accumulates in the culture broth, aftercompletion of the incubation the culture supernatant containing theluciferase mutant of the invention can be obtained by separating thebacteria or cells and the culture supernatant in a conventional manner(e.g., centrifugation, filtration, etc.).

The luciferase mutant of the invention contained in the extract orculture supernatant thus obtained can be purified by conventionalmethods of separation and purification. Examples of these methods forseparation and purification which may be used include ammonium sulfateprecipitation, gel filtration chromatography, ion-exchangechromatography, affinity chromatography, reversed-phase high-performanceliquid chromatography, dialysis, ultrafiltration, etc., alone or in asuitable combination thereof. When the luciferase mutant of theinvention contains the peptide sequence for purification describedabove, it is preferred to perform purification using the same.Specifically, when the luciferase mutant of the invention contains ahistidine tag sequence, nickel chelate affinity chromatography may beused; when the luciferase mutant of the invention contains the bindingdomain of S-transferase to glutathione, affinity chromatography with aglutathione-binding gel may be used; when the luciferase mutant of theinvention contains the amino acid sequence of Protein A, antibodyaffinity chromatography may be used.

5. Use of Luciferase Mutant of the Invention Use as Detection Marker byLuminescence

The luciferase mutant of the invention can be utilized as a detectionmarker (“detection marker for the invention”) which emits luminescencein the presence of a luciferin. The detection marker of the inventioncan be utilized for detection of the target substance in, e.g., animmunoassay, a hybridization assay, etc.

The luciferase mutant of the invention can be expressed, e.g., as afusion protein with a target protein, and introduced into cells by meansof the microinjection method, etc., and the resulting product can beused to determine distribution of the target protein described above.The distribution of such a target protein or the like can be determinedby using detection methods such as luminescence imaging. In addition tothe introduction into cells by means of the microinjection method or thelike, the luciferase mutant of the invention can be expressed in cellsto provide for use.

The luminescence substrate (luciferin) used is preferablycoelenterazines, and particularly preferably, coelenterazine, asdescribed above.

Use as Reporter Protein

The luciferase mutant of the invention may also be used as a reporterprotein to assay the transcription activity of promoters, etc. In thiscase, the polynucleotide of the invention is used as a reporter gene andthe luciferase mutant encoded by the reporter gene is contacted withluciferin. As used herein, the term “contact” is intended to mean thatthe luciferase mutant of the invention and a luciferin are allowed to bepresent in the same reaction system or culture system, which includes,for example, addition of a luciferin to a culture container charged withcells expressing the luciferase mutant of the invention, mixing thecells with a luciferin and incubation of the cells in the presence ofluciferin. The polynucleotide encoding the luciferase mutant of theinvention (i.e., the polynucleotide of the invention) is fused to atarget promoter or some other expression control sequence (e.g., anenhancer, etc.) to construct a vector. By introducing the vector into ahost cell and detecting the luminescence from the luciferase mutant ofthe invention in the presence of a luciferin (luminescence substrate),the activity of the target promoter or some other expression controlsequence can be assayed. Furthermore, the expressed luciferase mutant isreacted with coelenterazines and the luminescence generated may also bevisualized in pictures by using a high-sensitive detector.

The luciferin used is preferably coelenterazines, and particularlypreferably, coelenterazine, as described above.

The cells used are preferably animal cells. In the case of animal cells,the luciferase mutant in a preferred embodiment of the invention ishardly secreted outside the cells.

The polynucleotide of the invention can be used as a reporter gene insuch a manner as described above.

Material for Amusement Supplies

The luciferase mutant of the invention has the activity of catalyzingthe reaction where a luciferin is oxidized with oxygen molecules to formoxyluciferin in its excited state. The oxyluciferin in the excited stateemits visible light to decay to the ground state. Accordingly, theluciferase mutant of the invention can be used preferably as aluminescent material for amusement supplies. Examples of such amusementsupplies are luminescent soap bubbles, luminescent ice bars, luminescentcandies, luminescent color paints, etc. These amusement supplies of theinvention can be prepared in a conventional manner.

The luciferin used is preferably coelenterazines, and particularlypreferably, coelenterazine, as described above.

Bioluminescence Resonance Energy Transfer (BRET) Method

By utilizing the principle of interaction between molecules by thebioluminescence resonance energy transfer (BRET) method, the luciferasemutant of the invention is available for analytical methods such asanalysis of physiological functions, assay of enzyme activities, etc.

For instance, when the luciferase mutant of the invention is used as adonor and the fluorescent substance (e.g., an organic compound, afluorescent protein, etc.) is used as an acceptor, the interactionsbetween the donor and acceptor above can be detected by inducingbioluminescence resonance energy transfer (BRET) between them.

In an embodiment of the present invention, the organic compound used asan acceptor includes Hoechist3342, Indo-1, DAP1, etc. In anotherembodiment of the present invention, the fluorescent protein used as anacceptor includes a green fluorescent protein (GFP), a blue fluorescentprotein (BFP), a muted GFP fluorescent protein, phycobilin, etc.

In a preferred embodiment of the present invention, the physiologicalfunctions to be analyzed include an orphan receptor (especially, a Gprotein-coupled receptor), apoptosis, transcription regulation by geneexpression, etc. In a further preferred embodiment of the presentinvention, the enzyme to be analyzed is protease, esterase, kinase, orthe like.

Analysis of the physiological functions by the BRET method can beperformed by known methods, for example, by modifications of the methoddescribed in Biochem. J. 2005, 385, 625-637 or Expert Opin. Ther Tarets,2007 11: 541-556. Enzyme activities may also be assayed by knownmethods, for example, by modifications of the method described in NatureMethods 2006, 3:165-174 or Biotechnol. J. 2008, 3:311-324.

The luminescence substrate (luciferin) used is preferablycoelenterazines, and particularly preferably, coelenterazine, asdescribed above.

6. Kit of the Invention

The present invention also provides a kit comprising any one selectedfrom the luciferase mutant of the invention, the polynucleotide of theinvention, the recombinant vector of the invention and the transformantof the invention. The kit of the invention may further contain aluciferin.

The luciferin is preferably coelenterazines, and particularlypreferably, coelenterazine, as described above.

The kit of the present invention may be prepared with conventionalmaterials by conventional methods. The kit of the present invention mayfurther contain, e.g., sample tubes, plates, instructions for the kituser, solutions, buffers, reagents, and samples suitable forstandardization or control samples. The kit of the present invention mayfurther contain salts including halide ions.

The kit of the present invention can be used for the measurement usingthe reporter protein or reporter gene described above, the analysis ofphysiological functions by the BRET method, the measurement of enzymeactivities, and the like. The kit of the present invention can be usedfor the method for luminescence reaction as described below.

7. Method for Luminescence Reaction Luminescence Activity

The luciferase mutant of the invention has the ability of catalyzing thereaction which involves oxidization of a luciferin with oxygen moleculesto form an oxyluciferin in its excited state. The oxyluciferin in theexcited state emits light on returning to the ground state. That is, theluciferase mutant of the invention catalyzes the luminescence reactionin which a luciferin serves as a substrate to cause luminescence. Thisactivity is sometimes referred to as the “luminescence activity” herein.

Luminescence Reaction

The luminescence reaction using the luciferase mutant of the inventionin which a luciferin serves as a substrate can be performed bycontacting the luciferase mutant of the invention with the luciferin. Asused herein, the term “contact” is intended to mean that the luciferasemutant of the invention and a luciferin are allowed to be present in thesame reaction system, which includes, for example, addition of theluciferase mutant of the invention to a container charged with aluciferin, addition of a luciferin to a container charged with theluciferase mutant of the invention and mixing the luciferase mutant ofthe invention with a luciferin. The reaction can be carried out underconditions conventionally used for the luminescence reaction usingOplophorus luciferase or under conditions modified therefrom.

Specifically, solvents for the reaction which are employed are, forexample, a buffer solution such as Tris-HCl buffer, sodium phosphatebuffer, etc., water, and the like.

Temperatures for the reaction are generally at approximately 4° C. to40° C. and preferably approximately 4° C. to 25° C.

In the reaction solution, pH is generally approximately 5 to 10,preferably approximately 6 to 9, more preferably approximately 7 to 8and most preferably approximately 7.5.

The luciferin is preferably coelenterazines, and particularlypreferably, coelenterazine, as described above.

The luciferin may also be added to the reaction system in the form of asolution in a polar solvent such as dimethylformamide,dimethylsulfoxide, etc., or in an alcohol such as methanol, ethanol,butanol, etc.

Activation of Luminescence Activity

The luminescence activity of the luciferase mutant of the invention isactivated by halide ions, nonionic surfactants, etc.

Examples of the halide ions are fluorine ions, chlorine ions, bromineions and iodine ions; preferred are chlorine ions, bromine ions andiodine ions.

The concentration of the halide ions is generally approximately 10 μM to100 mM, preferably approximately 100 μM to 50 mM and particularlypreferably approximately 1 mM to 20 mM.

The addition of the halide ions to the reaction system is performed by amethod which comprises adding them in a salt form. The salts used arealkali metal salts such as sodium salts, potassium salts, etc.; alkalineearth metal salts such as calcium salts, magnesium salts, barium salts,etc. More specific examples are NaF, NaCl, NaBr, Nal, KF, KCl, KBr, KI,CaF₂, CaCl₂, CaBr₂, CaI₂, MgF₂, MgCl₂, MgBr₂, MgI₂, etc.

Examples of nonionic surfactants which are commercially available (tradename) include Tween 20 (polyoxyethylene sorbitan monolaurate), Tween 80(polyoxyethylene sorbitan monooleate), Triton X-100 (polyethyleneglycol-p-isooctylphenyl ether), Briji-58 (polyoxyethylene (20) cetylether), Nonidet P-40 (ethylphenolpoly(ethylene glycol ether)n), etc.,and preferably, Tween 20, Triton X-100, etc.

Concentration of the nonionic surfactant is generally approximately0.0002% (w/v) to 0.2% (w/v), preferably, approximately 0.001% (w/v) to0.1% (w/v), and particularly preferably, approximately 0.05% (w/v) to0.02% (w/v).

Regardless of their purposes, all of the documents and publicationsdescribed in the specification are incorporated herein by reference,each in its respective entirety.

Unless otherwise indicated with respect to the embodiments and workingexamples, the methods described in standard sets of protocols such as J.Sambrook, E. F. Fritsch & T. Maniatis (Ed.), Molecular cloning, alaboratory manual (4th edition), Cold Spring Harbor Press, Cold SpringHarbor, N.Y. (2012); F. M. Ausubel, R. Brent, R. E. Kingston, D. D.Moore, J. G. Seidman, J. A. Smith, K. Struhl (Ed.), Current Protocols inMolecular Biology, John Wiley & Sons Ltd., etc. or modifications orvariations thereof are used. When commercially available reagent kits ormeasuring apparatuses are used, protocols attached to them are usedunless otherwise indicated.

The objects, characteristics and advantages of the present invention aswell as the idea thereof are apparent to those skilled in the art fromthe descriptions given herein. Based on the description given herein,those skilled in the art can easily reproduce the present invention.

It can be understood that the embodiments of the invention, specificworking examples, etc. are disclosed as preferred embodiments of thepresent invention. These descriptions are only for illustrative andexplanatory purposes and are not intended to restrict the inventionthereto. It is further apparent to those skilled in the art that variousmodifications may be made based on the descriptions given herein withinthe intent and scope of the present invention disclosed herein.

EXAMPLES

Hereinafter, the present invention will be described with reference tospecific examples but is not deemed to be limited thereto.

Example 1: Preparation of Mutated 19kOLase Gene

Amino acid substitutions by site-specific mutagenesis on the gene for19kOLase (hereinafter designated as KAZ) were performed by PCR inaccordance with the method described in Ho et al., Gene (1989) 77:51-59. The nucleotide sequence and amino acid sequence of KAZ are shownin SEQ ID NO: 1 and SEQ ID NO: 2, respectively. Specifically, PCR (cycleconditions: 25 cycles of 1 min/94° C., 1 min/50° C., 1 min/72° C.) wasperformed using pCold-KAZ or pCold-ZZ-KAZ carrying the KAZ gene as atemperate with two PCR primers on a PCR kit (manufactured by Takara BioInc.).

For example, the gene for single amino acid substitution mutant KAZ-Q18Lwas produced as follows. First, DNA fragments amplified by the primerswere prepared using pCold-KAZ as a template.

Primer used to prepare the first DNA fragment: pCold-F (SEQ ID NO: 17)(5′ ACG CCA TAT CGC CGAAAG G 3′)  KAZ: Q18L-R (SEQ ID NO: 18) (5′TAA CAC TTG ATC TAG GTT GTA TCC AGC 3′)Primer used to prepare the second DNA fragment: KAZ: Q18L-F(SEQ ID NO: 19) (5′ GCT GGA TAC AAC CTA GAT CAA GTG TTA 3′) KAZ-5C/XbaI(SEQ ID NO: 20) (5′ CCGC TCT AGA TTA GGC AAG AAT GTT CTC GCA AAGCCT 3′) 

The two DNA fragments prepared above were amplified by a second PCRusing the PCR primers KAZ-8N/EcoRI and KAZ-5C/XbaI as below.

Primers: KAZ-8N/EcoRI (SEQ ID NO: 21) (5′GCG GAA TTC TTT ACG TTG GCA GAT TTC GTT GGA 3′) KAZ-5C/XbaI(SEQ ID NO: 20)

The results indicate that the KAZ gene region (KAZ-Q18L) wherein theamino acid of glutamine at the position of 18 was substituted by leucinein the amino acid sequence of SEQ ID NO: 2 was amplified.

Amino acid substitution was performed in the same manner as describedabove, using the templates and primers listed in TABLE 1 to acquire theamino acid substituted KAZ gene regions.

TABLE 1List of templates and PCR primers used for single amino acid substitutionof KAZ proteins Substi- tution position Template Primer Sequence A4E PCRpCold-ZZ-KAZ a KAZ: A4E-F 5′ ccg gaa ttc TTT ACG CTG GAG GAT TTC GTTGGA GAC 3′ (SEQ ID NO: 22) b KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) Q11RPCR pCold-ZZ-KAZ a KAZ: Q11R-F 5′ ccggaattcTTTACGTTGGCAGATTTCGTTGGAGACTGGCGACAGACAGCTGG 3′ (SEQ ID NO: 23) b KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) Q18L1st pCold-KAZ a pCold-F 5′ ACG CCA TAT CGC CGA AAG G 3′ (SEQ ID PCRNO: 17) b KAZ: Q18L-R 5′ TAA CAC TTG ATC TAG GTT GTA TCC AGC 3′(SEQ ID NO: 18) pCold-KAZ c KAZ: Q18L-F 5′GCT GGA TAC AAC CTA GAT CAA GTG TTA 3′ (SEQ ID NO: 19) d KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) 2nd1st PCR a KAZ-8N/EcoRI 5′ gcg GAA TTC TTT ACG TTG GCA GAT TTC PCRproduct GTT GGA 3′ (SEQ ID NO: 21) d KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) L27V1st pCold-KAZ a pCold-F 5′ ACG CCA TAT CGC CGA AAG G 3′ (SEQ ID PCRNO: 17) b KAZ: L27V-R 5′ GAA CAG ACT AGA CAC TCC TCC TTG TTC 3′(SEQ ID NO: 24) pCold-KAZ c KAZ: L27V-F 5′GAA CAA GGA GGA GTG TCT AGT CTG TTC 3′ (SEQ ID NO: 25) d KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) 2nd1st PCR a KAZ-8N/EcoRI 5′ gcg GAA TTC TTT ACG TTG GCA GAT TTC PCRproduct GTT GGA 3′ (SEQ ID NO: 21) d KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) A33N1st pCold-ZZ-KAZ a KAZ-8N/EcoRI 5′ gcg GAA TTC TTT ACG TTG GCA GAT TTCPCR GTT GGA 3′ (SEQ ID NO: 21) b A33N-R 5′TGA CAC TCC CAG GTT TTG GAA CAG ACT 3′ (SEQ ID NO: 26) pCold-ZZ-KAZ cA33N-F 5′ AGT CTG TTC CAA AAC CTG GGA GTG TCA 3′ (SEQ ID NO: 27) dKAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′(SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) K43R 1st pCold-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: K43R-R 5′ AGA CAG TAC AAC TCT CTG TAT GGG CGT 3′ (SEQ ID NO: 28)pCold-KAZ c KAZ: L43R-F 5′ ACG CCC ATA CAG AGA GTT GTA CTG TCT 3′(SEQ ID NO: 29) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) V44I 1st pCold-ZZ-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: V44I-R 5′ CCC AGA CAG TAC TAT TTT CTG TAT GGG 3′ (SEQ ID NO: 30)pCold-ZZ-KAZ c KAZ: V44I-F 5′ CCC ATA CAG AAA ATA GTA CTG TCT GGG 3′(SEQ ID NO: 31) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) A54I 1st pCold-ZZ-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: A54I-R 5′ GAC ATG AAT ATC GAT TTT TAA CCC ATT 3′ (SEQ ID NO: 32)pCold-ZZ-KAZ c KAZ: A54I-F 5′ AAT GGG TTA AAA ATC GAT ATT CAT GTC 3′(SEQ ID NO: 33) d pCold-R 5′ TGG CAG GGA TCT TAG ATT CTG 3' (SEQ IDNO: 34) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) F68D 1st pCold-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: F68D-R 5′ TAG ACC CAT TTG ATC ACC ACT GAG TCC 3′ (SEQ ID NO: 35)pCold-KAZ c KAZ: F68D-F 5′ GGA CTC AGT GGT GAT CAA ATG GGT CTA 3′(SEQ ID NO: 36) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) L72Q 1st pCold-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: L72Q-R 5′ GAT CAT TTC AAT TTG ACC CAT TTG AAA 3′ (SEQ ID NO: 37)pCold-KAZ c KAZ: L72Q-F 5′ TTT CAA ATG GGT CAA ATT GAAATG ATC 3′(SEQ ID NO: 38) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) M75K 1st pCold-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: M75K-R 5′ AAC TTT GAA GAT CTT TTC AAT TAG ACC 3′ (SEQ ID NO: 39)pCold-KAZ c KAZ: M75K-F 5′ GGT CTA ATT GAA AAG ATC TTC AAA GTT 3′(SEQ ID NO: 40) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) I90V 1st pCold-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: I90V-R 5′ ATA ATG GAG AAT AAC CTT GAA ATG ATG 3′ (SEQ ID NO: 41)pCold-KAZ c KAZ: I90V-F 5′ CAT CAT TTC AAG GTT ATT CTC CAT TAT 3′(SEQ ID NO: 42) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) P115E 1st pCold-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: P115E-R 5′ TAC AGC AAT TCC TTC GTA AGG TCT TCC 3′ (SEQ ID NO: 43)pCold-KAZ c KAZ: P115E-F 5′ GGA AGA CCT TAC GAA GGA ATT GCT GTA 3′(SEQ ID NO: 44) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) Q124K 1st pCold-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: Q124K-R 5′ AGT AAC TGT GAT CTT CTT GCC GTC AAA 3′ (SEQ ID NO: 45)pCold-KAZ c KAZ: Q124K-F 5′ TTT GAC GGC AAG AAG ATC ACA GTT ACT 3′(SEQ ID NO: 46) d pCold-R 5′ TGG CAG GGA TCT TAG ATT CTG 3′ (SEQ IDNO: 34) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) Y138I 1st pCold-ZZ-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR GTT GGA 3′ (SEQ ID NO: 21) bKAZ: Y138I-R 5′ TAG CCT CTC ATC AAT GAT CTT GTT GCC 3′ (SEQ ID NO: 47)pCold-ZZ-KAZ c KAZ: Y138I-F 5′ GGC AAC AAG ATC AFI GAT GAG AGG CTA 3′(SEQ ID NO: 48) d pCold-R 5′ TGG CAG GGA TCT TAG ATT CTG 3′ (SEQ IDNO: 34) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC PCR product GTT GGA 3′(SEQ ID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAG AAT GTT CTCGCA AAG CCT 3′ (SEQ ID NO: 20) N166R PCR pCold-ZZ-KAZ a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG GCA GAT TTC GTT GGA 3′ (SEQ ID NO: 21) bKAZ: N166R-R 5′ gcc TCT AGA TTA GGC AAG AAT CCT CTC GCA AAG 3′(SEQ ID NO: 49)

Example 2: Preparation of Mutated 19kOLase Gene (dnKAZ) with 16Mutations

Using pCold-ZZ-P-nanoKAZ described in Inouye et al. (2013) Biochem.Biophys. Res. Commun. 437: 23-28, gene amplification was performed byPCR using the following primers.

Primers: nanoKAZ-1N/EcoRI (SEQ ID NO: 50) (5′gcgGAATTCTTCACCCTGGAGGACTTCGTCGGC 3′: EcoRI sequence underlined)nanoKAZ-3C/XbaI (SEQ ID NO: 51) (5′gccTCTAGATTAGGCCAGGATTCTCTCGCACAGTCT 3′: XbaI sequence underlined)

Example 3: Construction of Expression Vectors for KAZ Mutant Using pCold II Vector in E. coli

The DNA fragments obtained in EXAMPLES 1 and 2 were purified on a PCRpurification kit (manufactured by Qiagen Inc.), digested withrestriction enzymes EcoRI/XbaI in a conventional manner and then ligatedto an expression vector pCold II (Takara Bio Inc.) at the restrictionenzyme EcoRI/XbaI site to construct the KAZ mutant vectors as follows:pCold-KAZ-A4E, pCold-KAZ-Q11R, pCold-KAZ-Q18L, pCold-KAZ-L27V,pCold-KAZ-A33N, pCold-KAZ-K43R, pCold-KAZ-V44I, pCold-KAZ-A54I,pCold-KAZ-F68D, pCold-KAZ-L72Q, pCold-KAZ-M75K, pCold-KAZ-I90V,pCold-KAZ-P115E, pCold-KAZ-Q124K, pCold-KAZ-Y138I, pCold-KAZ-N166R andpCold-dnKAZ. The nucleotide sequences of the insert DNAs were confirmedby sequencing using a DNA Sequencer (manufactured by ABI Inc.).

In the amino acid sequences of the KAZ mutants, substituted amino acidsand nucleotides are shown in TABLE 2.

TABLE 2 Nucleotide Sequence KAZ Before After Mutant SubstitutionSubstitution (KAZ-) (wild) (mutant) A4E 10 GCA (A) 10 GAG (E) Q11R 31CAA (Q) 31 AGA (R) Q18L 52 CAA (Q) 52 CTG (L) L27V 79 TTG (L) 79 GTC (V)A33N 33 GCA (A) 33 AAC (N) K43R 127 AAA (K) 127 AGA (R) V44I 130 GTT (V)130 ATC (I) A54I 160 GCT (A) 160 ATC (I) F68D 202 TTT (F) 202 GAC (D)L72Q 214 CTA (L) 214 CAG (Q) M75K 223 ATG (M) 223 AAG (K) I90V 268 ATT(I) 268 GTC (V) P115E 343 CCT (P) 343 GAG (E) Q124K 370 CAG (Q) 370 AAG(K) Y138I 412 TAT (Y) 412 ATC (I) N166R 496 AAC (N) 496 AGA (R)

In the KAZ mutants, the nucleotide sequence and amino acid sequence ofKAZ-V44I are shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively. Thenucleotide sequence and amino acid sequence of KAZ-A54I are shown in SEQID NO: 5 and SEQ ID NO: 6, respectively. The nucleotide sequence andamino acid sequence of KAZ-Y138I are shown in SEQ ID NO: 7 and SEQ IDNO: 8, respectively.

Example 4: Expression of KAZ Mutants in E. coli and Preparation of CrudeEnzyme Solution

In order to express the KAZ mutants in E. coli, the recombinant plasmidprepared in EXAMPLE 3 was used. The E. coli BL21 strain (Novagen,Madison, Wis.) was used as a host cell. The BL21 strain carrying therecombinant plasmid was incubated in 5 mL of Luria-Bertani medium(hereinafter designated as LB medium) containing ampicillin (50 μg/mL)at 37° C. for 18 hours. This seed culture, 0.1 mL, was inoculated to 10mL of LB medium and incubated for 3 hours, followed by cooling in anice-water bath for 1 hour. IPTG was added to the culture medium at afinal concentration of 1 mM, followed by incubation at 15° C. forfurther 20 hours. After completion of the incubation, 1 mL of thecultured medium was harvested by centrifugation at 10,000 rpm for 2minutes. The thus collected E. coli cells were suspended in 0.5 mL of 30mM Tris-HCl (pH 7.6)-10 mM EDTA (manufactured by Wako Pure ChemicalIndustries, Ltd.) (hereinafter designated as TE). The E. coli cells weredisrupted by sonication for 3 seconds using a Branson Model 250 Sonifier(Danbury, Conn.) to give a crude enzyme solution. After 0.5 mL of thecrude enzyme solution was further centrifuged at 10,000 rpm for 2minutes to separate the supernatant from the precipitate, theprecipitate was suspended in 0.5 mL of TE. Then 20 μL each of thesupernatant and precipitate were analyzed by SDS-PAGE to confirm thepresence or absence of soluble and insoluble proteins. The results areshown in FIG. 1, wherein M and 1 to 17 denote: M: molecular weight sizemarkers; 1: KAZ; 2 KAZ-A4E; 3: KAZ-Q11R; 4: KAZ-Q18L; 5: KAZ-L27V; 6:KAZ-A33N; 7: KAZ-K43R; 8: KAZ-V44I; 9: KAZ-A54I; 10: KAZ-F68D; 11:KAZ-L72Q; 12: KAZ-M75K; 13: KAZ-I90V; 14: KAZ-P115E; 15: KAZ-Q124K; 16:KAZ-Y138I; 17: KAZ-N166R and 18: dnKAZ. It is clearly observed from FIG.1 that only dnKAZ (18) was expressed as a soluble protein and the otherproteins (1 to 16) were expressed mostly as insoluble proteins.

Example 5: Assay for Luminescence Activity of KAZ Mutants in CrudeEnzyme Solution

A luminescence reaction was started by the addition of 5 μL each of thesupernatant and precipitate obtained in EXAMPLE 4 to 100 μL of TEcontaining 0.5 fig of coelenterazine (manufactured by JNC Corp.). Theluminescence activity was measured for 60 seconds using a luminometer(manufactured by Atto Corp.: AB2200) and expressed in terms of relativeluminescence activity (I_(max)).

TABLE 3 Luminescence activities of the supernatant and precipitatefractions in KAZ mutants in crude enzyme solutions Expression RelativeLuminescence Vector Activity (I_(max)) (pCold-) Supernatant PrecipitateKAZ 1.0 0.1 KAZ-A4E 1.5 0.2 KAZ-Q11R 2.0 0.3 KAZ-Q18L 1.0 0.2 KAZ-L27V0.1 0.1 KAZ-A33N 1.0 0.4 KAZ-K43R 1.8 0.2 KAZ-V44I 6.5 0.6 KAZ-A54I 15013 KAZ-F68D 5.4 0.2 KAZ-L72Q 7.2 0.6 KAZ-M75K 4.6 0.4 KAZ-I90V 2.1 0.4KAZ-P115E 16 1.1 KAZ-Q124K 7.4 0.8 KAZ-Y138I 32 1.4 KAZ-N166R 4.7 0.8dnKAZ 1,806 10

dnKAZ was expressed as a soluble protein and showed high luminescenceactivity in the supernatant. On the other hand, the KAZ mutants werealmost all expressed as insoluble proteins and the luminescence activitywas low in the supernatant and precipitate fractions. Among others, theKAZ-A54I mutant exhibited the activity of approximately 1/12 times thatof dnKAZ; the luminescence activity was enhanced by substituting alanineat the position of 54 with isoleucine.

Example 6: Construction of Expression Vectors for ZZ-Fused KAZ Mutantsin E. coli

To express KAZ mutants as soluble proteins, the expression vector ofpCold-ZZ-X (described in Inouye & Sahara, Protein Express. Purif. (2009)66: 52-57) was used. The DNA fragments obtained in EXAMPLES 1 and 2 weredigested with restriction enzyme EcoRI/XbaI and ligated to therestriction enzyme EcoRI/XbaI site of this expression vector toconstruct the following expression vectors for the fused KAZ mutants:pCold-ZZ-P-KAZ-A4E, pCold-ZZ-P-KAZ-Q11R, pCold-ZZ-P-KAZ-Q18L,pCold-ZZ-P-KAZ-L27V, pCold-ZZ-P-KAZ-A33N, pCold-ZZ-P-KAZ-K43R,pCold-ZZ-P-KAZ-V44I, pCold-ZZ-P-KAZ-A54I, pCold-ZZ-P-KAZ-F68D,pCold-ZZ-P-KAZ-L72Q, pCold-ZZ-P-KAZ-M75K, pCold-ZZ-P-KAZ-I90V,pCold-ZZ-P-KAZ-P115E, pCold-ZZ-P-KAZ-Q124K, pCold-ZZ-P-KAZ-Y138I,pCold-ZZ-P-KAZ-N166R, and pCold-ZZ-P-dnKAZ.

Example 7: Expression of ZZ-Fused KAZ Mutants in E. coli and Preparationof Crude Enzyme Solution

To express the ZZ-fused KAZ mutants in E. coli, the recombinant plasmidprepared in EXAMPLE 6 was used. Crude enzyme solutions were prepared inthe same manner as EXAMPLE 4 using the E. coli BL21 strain (Novagen,Madison, Wis.) as a host cell. The resultant crude enzyme solution, 5μL, was subjected to SDS-PAGE analysis to confirm expression of theproteins (FIG. 2). In FIG. 2, M and 1 to 18 are the same as described inFIG. 1.

Example 8: Assay for Luminescence Activity of ZZ-Fused KAZ Mutants inCrude Enzyme Solutions

DTT was added to the crude enzyme solution obtained in EXAMPLE 7 at afinal concentration of 1 mM and the mixture was allowed to stand in anice water for more than 5 hours. A luminescence reaction was started byadding 1 μL of the crude enzyme solution to 100 μL of TE containing 1 μgof coelenterazine (manufactured by JNC Corp.). The luminescence activitywas determined using a luminometer (manufactured by Atto Inc.: AB2200)for 60 seconds, and the maximum intensity of luminescence (I_(max)) wasshown as relative luminescence activity.

The results are shown in TABLE 4. It was confirmed by the results ofTABLE 4 that the activities of three mutants of KAZ-V44I, KAZ-A54I andKAZ-Y138I were stimulated by 6.6, 8.9 and 5.9 times higher than that ofwild KAZ, respectively. In particular, KAZ-A54I with a single mutationexhibited the luminescence activity comparable to dnKAZ with 16 aminoacid mutations, suggesting that the three substitutions may be criticalfor luminescence enhancement.

TABLE 4 Luminescence activities of ZZ-fused KAZ mutants in crude enzymesolutions Relative Luminescence Expression Vector Activity (pCold-ZZ-P-)(I_(max)) KAZ 1.0 KAZ-A4E 0.5 KAZ-Q11R 1.8 KAZ-Q18L 0.3 KAZ-L27V 0.1KAZ-A33N 1.0 KAZ-K43R 0.6 KAZ-V44I 6.6 KAZ-A54I 8.9 KAZ-F68D 2.7KAZ-L72Q 2.5 KAZ-M75K 1.3 KAZ-I90V 1.8 KAZ-P115E 4.5 KAZ-Q124K 3.7KAZ-Y138I 5.9 KAZ-N166R 3.6 dnKAZ 9.4

Example 9: Secretory Expression Vectors for KAZ Mutants Using a SignalPeptide Sequence of Gaussia Luciferase for Secretion

Expression vectors for the KAZ mutants were constructed as follows.First, a novel expression vector pcDNA3-GLsp for animal culture cellswas constructed. Specifically, a signal peptide sequence of Gaussialuciferase for secretion was obtained from the pcDNA3-GLuc vector(manufactured by Prolume Ltd.) by PCR using the following primers.

Primers: GLsp-1R/EcoRI (SEQ ID NO: 52) (5′ggc GAA TTC GGT GGG CTT GGC CTC GGC CAC 3′, EcoRI sequence underlined)T7 Primer (SEQ ID NO: 53) (5′ TAATACG ACTCACTATAGGG 3′)

The resulting fragment of the signal peptide sequence for secretion wasdigested with HindIII/EcoRI and inserted into the restriction enzymeHindIII/EcoRI site of pcDNA3 vector (manufactured by Invitrogen Inc.) toconstruct a novel expression vector pcDNA3-GLsp. The novel expressionvector is regulated by CMV promoter, followed by the Kozak sequence, thesignal pepetide sequence of Gaussia luciferase for secretion and amultiple-cloning site sequence.

Next, expression vectors for the KAZ mutants were constructed using thenovel expression vector of pcDNA3-GLsp as follows. The KAZ mutant genefragment was digested with restriction enzymes EcoRI/XbaI in aconventional manner and then ligated to the EcoRI-XbaI site ofpcDNA3-GLsp to construct the following expression vectors:pcDNA3-GLsp-KAZ-A4E, pcDNA3-GLsp-KAZ-Q11R, pcDNA3-GLsp-KAZ-Q18L,pcDNA3-GLsp-KAZ-L27V, pcDNA3-GLsp-KAZ-A33N, pcDNA3-GLsp-KAZ-K43R,pcDNA3-GLsp-KAZ-V44I, pcDNA3-GLsp-KAZ-A54I, pcDNA3-GLsp-KAZ-F68D,pcDNA3-GLsp-KAZ-L72Q, pcDNA3-GLsp-KAZ-M75K, pcDNA3-GLsp-KAZ-I90V,pcDNA3-GLsp-KAZ-P115E, pcDNA3-GLsp-KAZ-Q124K, pcDNA3-GLsp-KAZ-Y138I,pcDNA3-GLsp-KAZ-N166R and pcDNA3-GLsp-dnKAZ. The inserted gene sequenceswere confirmed by sequencing using a DNA Sequencer (manufactured by ABIInc.).

Example 10: Transfection of Vectors in Animal Culture Cells andPreparation of Enzyme for Assay (1) Purification of Expression Plasmid

The following experiment was conducted using the recombinant plasmidobtained in EXAMPLE 9. The recombinant plasmid was purified from the E.coli JM83 strain using a plasmid purification kit (manufactured byQIAGEN) and dissolved in sterilized water. Firefly luciferase vector(pGL4.13 [Luc2/sv40]: manufactured by Promega Corp.) was similarlytreated and used as an internal standard.

(2) Transfection and Preparation of Enzyme for Assay

Chinese hamster ovary cell line CHO-K1 was cultured in Ham's F-12 medium(manufactured by Wako Pure Chemical Industries, Ltd.) supplemented with10% (v/v) fetal bovine serum (manufactured by Biowest Inc.). The CHO-K1cells were plated in a 6-well plate in 1×10⁵ cells/well/2 mL medium(n=2) and cultured in an incubator at 37° C. in 5% (v/v) CO₂. After 24hours, the purified recombinant plasmid was transfected to CHO-K1 cellsusing a FuGene HD transfection kit (manufactured by Promega Corp.),which was provided for subsequent experiment. Specifically, 1 μg of therecombinant plasmid pGL4.13 [Luc2/sv40], 0.1 μg of the internal standardvector and 3 μL of FuGene HD were added to 100 μL of the medium, whichwas allowed to stand at room temperature for 15 minutes. Subsequently,100 μL of the DNA-FuGene complex was added to the cells in the 6 wells.After incubation for 48 hours, the culture medium was collected. On theother hand, the KAZ mutants expressed in the cells were washed 3 timeswith 3 mL of 1×PBS, then suspended in 1 mL of 1×PBS and disrupted on iceby ultrasonication, which was used as enzyme solutions of thecell-extracts of KAZ mutants.

Example 11: Measurement of Luminescence Activity of KAZ MutantsExpressed in Animal Culture Cells

A luminescence reaction was started by adding 5 μL of the culture mediaand cell extracts obtained in EXAMPLE 10 to 100 μL of 30 mM Tris-HCl (pH7.6)-10 mM EDTA (manufactured by Wako Pure Chemical Industries, Ltd.)containing 0.5 μg of coelenterazine (manufactured by INC Corp.). Theluminescence activity was determined using a luminometer (manufacturedby Atto Inc.: AB2200) for 60 seconds, and the maximum intensity ofluminescence (Imax) was defined as a percentage. The results are shownin TABLE 5. In the results of TABLE 5, no secretion from the cells wasobserved in any of the KAZ mutants with single amino acid substitution.

In firefly luciferase which was used as the internal standard to confirmthe efficiency of transfection, 5 μL of the cell extract obtained inEXAMPLE 10 was added to 100 μL of a reagent for enzyme assay (PromegaCorp.) to start a luminescence reaction. The luminescence activity wasdetermined as the maximum intensity of luminescence in terms of relativelight unit (rlu) for 10 seconds using a luminometer (manufactured byAtto Inc.: AB2200). It was confirmed that the transfection efficiencieswere almost the same.

TABLE 5 Luminescence activities of KAZ mutants expressed in animalculture cells Expression Relative Luminescence Activity Vector (I_(max))(%) (pcDNA3-GLsp-) Culture Medium Cell Extracts KAZ less than 0.01 0.1KAZ-A4E less than 0.01 0.1 KAZ-Q11R less than 0.01 0.1 KAZ-Q18L lessthan 0.01 0.02 KAZ-L27V less than 0.01 0.02 KAZ-A33N less than 0.01 0.1KAZ-K43R less than 0.01 0.1 KAZ-V44I less than 0.01 0.7 KAZ-A54I lessthan 0.01 2.4 KAZ-F68D less than 0.01 0.3 KAZ-L72Q less than 0.01 0.4KAZ-M75K less than 0.01 0.2 KAZ-I90V less than 0.01 0.3 KAZ-P115E lessthan 0.01 0.3 KAZ-Q124K less than 0.01 0.3 KAZ-Y138I less than 0.01 1.0KAZ-N166R less than 0.01 0.2 nanoKAZ 100 6.5

Example 12: Construction of Genes for the KAZ Mutants with Two AminoAcid Substitutions and Three Amino Acid Substitutions

Based on the results in EXAMPLE 8 that three amino acid substitutions(V44I, A54I, Y138I) may be critical for luminescence enhancement, themutants with these two amino acid substitutions and three amino acidsubstitutions were constructed to examine the luminescence activity.

The genes for KAZ mutants with two amino acid substitutions and threeamino acid substitutions were obtained in the same manner as EXAMPLE 1using the single amino acid substituted KAZ mutant prepared in EXAMPLE 5as a template and the PCR primers described in TABLE 6.

By the methods as described above, the mutated regions of KAZ gene forthree mutants with two amino acid substitutions (KAZ-V44I-A54I,KAZ-V44I-Y138I and KAZ-A54I-Y138I) and one mutant with three amino acidsubstitutions (KAZ-V44I-A54I-Y138I) were obtained.

TABLE 6List of templates and PCR primers used for KAZ proteins with two andthree amino acid substitutions Substitution position Template PrimerSequence V44I-A54I 1st pCold-ZZ-P- a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG PCR V44I-KAZ GCA GAT TTC GTT GGA 3′ (SEQID NO: 21) b KAZ: A54I-R 5′ GAC ATG AAT ATC GAT TTT TAA CCC ATT 3′(SEQ ID NO: 32) pCold-ZZ-P- c KAZ: A54I-F 5′ AAT GGG TTA AAA ATC GATV44I-KAZ ATT CAT GTC 3′ (SEQ ID NO: 33) d KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ SEQ ID NO: 20) 2nd1st PCR a KAZ-8N/EcoRI 5′ gcg GAA TTC TTT ACG TTG PCR productGCA GAT TTC GTT GGA 3′ (SEQ ID NO: 21) d KAZ-5C/XbaI 5′ccgc TCT AGA TTA GGC AAG AAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20)V44I-Y138I 1st pCold-ZZ-P- a KAZ-8N/EcoRI 5′ gcg GAA TTC TTT ACG TTG PCRY138I-KAZ GCA GAT TTC GTT GGA 3′ (SEQ ID NO: 21) b KAZ: V44I-R 5′CCC AGA CAG TAC TAT TTT CTG TAT GGG 3′ (SEQ ID NO: 30) pCold-ZZ-P- cKAZ: V44I-F 5′ CCC ATA CAG AAA ATA GTA Y138I-KAZ CTG TCT GGG 3′(SEQ ID NO: 31) 5′ ccgc TCT AGA TTA GGC AAG d KAZ-5C/XbaIAAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG PCR product GCA GAT TTC GTT GGA 3′ (SEQID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAGAAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) A54I-Y138I 1st pCold-ZZ-P- aKAZ-8N/EcoRI 5′ gcg GAA TTC TTT ACG TTG PCR Y138I-KAZGCA GAT TTC GTT GGA 3' (SEQ ID NO: 21) b KAZ: A54I-R 5′GAC ATG AAT ATC GAT TTT TAA CCC ATT 3′ (SEQ ID NO: 32) pCold-ZZ-P- cKAZ: A54I-F 5′ AAT GGG TTA AAA ATC GAT Y138I-KAZ ATT CAT GTC 3′(SEQ ID NO: 33) 5′ ccgc TCT AGA TTA GGC AAG d KAZ-5C/XbaIAAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG PCR product GCA GAT TTC GTT GGA 3′ (SEQID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAGAAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) V44I-A54I- 1st pCold-ZZ-P- aKAZ-8N/EcoRI 5′ gcg GAA TTC TTT ACG TTG Y138I PCR V44I-Y138I-GCA GAT TTC GTT GGA 3′ (SEQ KAZ ID NO: 21) b KAZ: A54I-R 5′GAC ATG AAT ATC GAT TTT TAA CCC ATT 3′ (SEQ ID NO: 32) pCold-ZZ-P- cKAZ: A54I-F 5′ AAT GGG TTA AAA ATC GAT V44I-Y138I- ATT CAT GTC 3′(SEQ ID NO: 33) KAZ 5′ ccgc TCT AGA TTA GGC AAG d KAZ-5C/XbaIAAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20) 2nd 1st PCR a KAZ-8N/EcoRI 5′gcg GAA TTC TTT ACG TTG PCR product GCA GAT TTC GTT GGA 3′ (SEQID NO: 21) d KAZ-5C/XbaI 5′ ccgc TCT AGA TTA GGC AAGAAT GTT CTC GCA AAG CCT 3′ (SEQ ID NO: 20)

Example 13: Construction of Expression Vectors for KAZ Mutants with TwoAmino Acid Substitutions and Three Amino Acid Substitutions Using p ColdII Vector E. coli

The DNA fragment obtained in EXAMPLE 12 was purified with a PCRpurification kit (manufactured by QIAGEN Inc.), digested withrestriction enzymes EcoRI/XbaI and then ligated to the restrictionenzyme EcoRI/XbaI site of the expression vector pCold II (Takara BioInc.) to construct the expression vectors of pCold-KAZ-V44I-A54I,pCold-ZZ-V44I-Y138I, pCold-KAZ-A54I-Y138I and pCold-KAZ-V44I-A54I-Y138Ifor the KAZ mutants. The nucleotide sequences of the insert DNAs wereconfirmed by sequencing using a DNA Sequencer (manufactured by ABIInc.).

In the amino acid sequences of the KAZ mutants, the substituted aminoacids and nucleotides are shown in TABLE 7.

TABLE 7 Substituted amino acids and nucleotides of KAZ mutants KAZNucleotide Sequence Mutants Before Substitution After Substitution(KAZ-) (wild) (mutant) V44I-A54I 130 GTT (V), 160 GCT (A) 130 ATC (I),160 ATC (I) V44I-Y138I 130 GTT (V), 412 TAT (Y) 130 ATC (I), 412 ATC (I)A54I-Y138I 160 GCT (A), 412 TAT (Y) 160 ATC (I), 412 ATC (I) V44I-A54I-130 GTT (V), 160 GCT (A), 130 ATC (I), 160 ATC (I), Y138I 412 TAT (Y)412 ATC (I)

Herein, the nucleotide sequence and amino acid sequence of KAZ-V44I-A54Iare shown by SEQ ID NO: 9 and SEQ ID NO: 10, respectively. Thenucleotide sequence and amino acid sequence of KAZ-V44I-Y138I are shownby SEQ ID NO: 11 and SEQ ID NO: 12, respectively. The nucleotidesequence and amino acid sequence of KAZ-A54I-Y138I are shown by SEQ IDNO: 13 and SEQ ID NO: 14, respectively. The nucleotide sequence andamino acid sequence of KAZ-V44I-A54I-Y138I are shown by SEQ ID NO: 15and SEQ ID NO: 16, respectively.

Example 14: Expression of KAZ Mutants in E. coli and Preparation ofCrude Enzyme Solutions

To express the KAZ mutants with two amino acid substitutions and threeamino acid substitutions in E. coli using a pCold II vector, therecombinant plasmid constructed in EXAMPLE 13 and pCold-V44I-KAZ,pCold-A54I-KAZ, pCold-Y138I-KAZ prepared in EXAMPLE 3 were used. Thesupernatant and precipitate of each crude enzyme solution were preparedin the same manner as EXAMPLE 4, using the E. coli BL21 starin (Novagen,Madison, Wis.) as a host cell. The supernatant and precipitate, 20 μLeach, were subjected to SDS-PAGE analysis to confirm the presence orabsence of soluble proteins and insoluble proteins. The results areshown in FIG. 3. In FIG. 3, M and 1 to 9 are as follows. M: molecularweight markers; 1: dnKAZ; 2: KAZ; 3: KAZ-V44I-A54I; 4: KAZ-V44I-Y138I;5: KAZ-A54I-Y138I; 6: KAZ-V44I-A54I-Y138I; 7: KAZ-V44I; 8: KAZ-A54I; and9: KAZ-Y138I. The results of FIG. 3 reveal that only dnKAZ was expressedas a soluble protein and the other mutants and KAZ were expressed asinsoluble proteins.

Example 15: Determination of Luminescence Activity of KAZ Mutants inCrude Enzyme Solutions

The luminescence activities of 5 μL each of the supernatant andprecipitate obtained in EXAMPLE 14 were determined in the same manner asEXAMPLE 5. The luminescence activity was assayed with a luminometer(manufactured by Atto Inc.: AB2200) for 60 seconds, and the maximumintensity of luminescence (I_(max)) was shown as relative luminescenceactivity.

The results are shown in TABLE 8. As shown in TABLE 8, nevertheless theKAZ mutants were expressed as insoluble proteins, the KAZ mutants withtwo amino acid substitutions of KAZ-V44I-A54I, KAZ-V44I-Y138I andKAZ-A54I-Y138I in the supernatants showed 295-fold, 71-fold and 982-foldhigher activities, respectively, as compared to the wild KAZ. Inparticular, the KAZ mutants with three amino acid substitutions showedhigh luminescence activities comparable to dnKAZ, suggesting that thesethree amino acids may be associated with luminescence enhancement ofKAZ.

TABLE 8 Luminescence activities of the supernatant and precipitatefractions in crude enzyme solutions of the mutants Relative LuminescenceExpression Vector Activity (I_(max)) (pCold-) Supernatant PrecipitateKAZ 1.0 0.1 KAZ-V44I 6.5 0.6 KAZ-A54I 151 13 KAZ-Y138I 32 1.4KAZ-V44I-A54I 295 5.8 KAZ-V44I-Y138I 71 5.0 KAZ-A54I-Y138I 982 21KAZ-V44I-A54I-Y138I 1,730 40 dnKAZ 1,809 10

Example 16: Construction of ZZ-Fused KAZ Mutants with Two Amino AcidSubstitutions and Three Amino Acid Substitutions in E. coli

To express as a soluble protein, the DNA fragment obtained in EXAMPLE 12was fused to the ZZ domain. The pCold-ZZ-P vector was used in the samemanner as EXAMPLE 6 to construct four expression vectors for expressingthe KAZ mutants fused to the ZZ domain: pCold-ZZ-P-KAZ-V44I-A54I,pCold-ZZ-P-KAZ-V44I-Y 138I, pCold-ZZ-P-KAZ-A54I-Y138I andpCold-ZZ-P-KAZ-V44I-A54I-Y138I.

Example 17: Expression of KAZ Mutants with Two Amino Acid Substitutionsand Three Amino Acid Substitutions in E. coli and Preparation of CrudeEnzyme Solutions

To express the ZZ-fused KAZ mutants in E. coli, the recombinant plasmidconstructed in EXAMPLE 16 and pCold-ZZ-P-V44I-KAZ, pCold-ZZ-P-A54I-KAZ,pCold-ZZ-P-Y138I-KAZ prepared in EXAMPLE 6 were used. Crude enzymesolutions were prepared in the same manner as EXAMPLE 7, using the E.coli BL21 strain (Novagen, Madison, Wis.) as a host cell. DTT was addedto the crude enzyme solutions at a final concentration of 1 mM. Themixtures were allowed to stand over 5 hours on ice, and luminescenceactivities were then assayed. The luminescence activities weredetermined by the method described in EXAMPLE 8. Also, 5 μL of theresultant crude enzyme solutions were subjected to SDS-PAGE analysis toconfirm protein expression (FIG. 4). In FIG. 4, M and 1 to 9 are asfollows. M: molecular weight size markers; 1: ZZ-P-KAZ; 2:ZZ-P-KAZ-V44I; 3: ZZ-P-KAZ-A54I; 4: ZZ-P-KAZ-Y138I; 5:ZZ-P-KAZ-V44I-A54I; 6: ZZ-P-KAZ-V44I-Y138I; 7: ZZ-P-KAZ-A54I-Y138I; 8:ZZ-P-KAZ-V44I-A54I-Y138I; and 9: ZZ-P-dnKAZ.

TABLE 9 Luminescence activities of ZZ-fused KAZ mutants in crude enzymesolutions Relative Luminescence Expression Vector Activity (pCold-ZZ-P-)(I_(max)) KAZ 1.0 KAZ-V44I 7.2 KAZ-A54I 8.4 KAZ-Y138I 7.5 KAZ-V44I-A54I15.3 KAZ-V44I-Y138I 17.1 KAZ-A54I-Y138I 23.1 KAZ-V44I-A54I-Y138I 66.7dnKAZ 9.4

The results of TABLE 9 reveal that the three mutants of KAZ-V44I-A54I,KAZ-V44I-Y138I and KAZ-A54I-Y138I with two amino acid substitutionsshowed 15-fold, 17-fold and 23-fold higher activity, respectively, andthe mutant KAZ-V44I-A54I-Y138I with three amino acid substitutionsshowed 67-fold higher activity, than wild KAZ.

In contrast to the relative activity of 9.4 for dnKAZ, the mutants withtwo amino acid substitutions of KAZ-V44I-A54I, KAZ-V44I-Y138I andKAZ-A54I-Y138I showed 1.6-fold, 1.8-fold and 2.5-fold higher activitiesthan dnKAZ, having 9.4-fold higher activity than KAZ, respectively, andthe mutant KAZ-V44I-A54I-Y138I with three amino acid substitutionsshowed 7.1-fold higher activity than dnKAZ. The results reveal thatthese three amino acids are critical for enhancement of the luminescenceactivities.

Example 18: Substrate Specificities of KAZ Mutants with Two Amino AcidSubstitutions and KAZ Mutants with Three Amino Acid Substitutions

The coelenterazine analogues used for substrate specificity studies weresynthesized by the methods described in publications. Specifically,bis-coelenterazine was synthesized by the method described in Nakamuraet al. (1997) Tetrahedron Lett. 38: 6405-6406; furimazine by the methoddescribed in Hall et al. (2012) ACS Chem. Biol. 16; 848-1857; and,6h-coelenterazine, f-coelenterazine and 6h-f-coelenterazine by themethods described in Inouye et al (2013) Biochem. Biophys. Res. Commun.437: 23-28.

DTT was added to the crude enzyme solutions obtained in EXAMPLE 17 at afinal concentration of 1 mM and the mixtures were allowed to stand in anice water for more than 5 hours in the same manner as Example 8. Aluminescence reaction was started by the addition of 1 μL each of thecrude enzyme solutions to 100 μL of TE containing 1 μg of coelenterazine(manufactured by JNC Corp.) or its analogues. The luminescenceactivities were determined using a luminometer (manufactured by AttoInc.: AB2200) for 60 seconds, and the maximum intensity of luminescence(I_(max)) was shown as relative luminescence activity.

The results are shown in TABLE 10. The results of TABLE 10 reveal that,when coelenterazine was used as a substrate, the mutants with two aminoacid substitutions and the mutants with three amino acid substitutionsshowed higher luminescence activities than dnKAZ, in particular, themutants with three amino acid substitutions showed highest luminescenceactivities.

The mutant of KAZ-V44I-A54I-Y138I with three amino acid substitutionsalso showed higher luminescence activity than dnKAZ with6h-coelenterazine.

It was revealed that the mutants of KAZ-V44I-A54I, KAZ-V44I-Y138I,KAZ-A54I-Y138I and KAZ-V44I-A54I-Y138I show high substrate specificityfor coelenterazine.

TABLE 10 Substrate specificities of KAZ mutants Relative LuminescenceActivity CTZ h-CTZ 6h-CTZ bis-CTZ f-CTZ 6h-f-CTZ Furimazine KAZ MutantI_(max) Int. I_(max) Int. I_(max) Int. I_(max) Int. I_(max) Int. I_(max)Int. I_(max) Int. KAZ 1.0 1.0 1.1 0.7 0.1 0.2 0.6 0.9 0.9 0.8 0.6 0.70.4 0.5 V44I 7.2 5.9 3.7 2.2 0.4 0.6 1.1 1.4 2.1 2.0 0.6 0.7 0.6 0.9A54I 8.4 9.0 11.8 6.9 1.6 2.1 3.0 3.4 8.2 4.9 1.6 2.0 2.0 2.1 Y138I 7.55.9 3.9 3.0 0.2 0.3 1.3 1.5 2.4 2.4 0.6 0.8 0.6 0.8 V44I-A54I 15.3 12.717.9 8.7 4.5 5.6 5.7 5.9 11.3 5.2 3.2 4.0 3.4 4.3 V44I-Y138I 17.1 9.919.1 9.7 4.3 5.3 7.9 8.3 13.3 7.4 3.6 4.2 5.1 5.4 A54I-Y138I 23.1 19.124.2 12.9 5.8 6.1 9.5 9.2 19.7 9.2 5.2 5.7 5.9 5.8 V44I-A54I-Y138I 66.766.7 83.1 33.2 12.9 11.1 13.3 11.9 43.8 9.5 9.5 9.6 10.6 9.2 dnKAZ (16mutants) 9.1 7.9 161.2 109.1 6.8 4.8 112.0 90.2 146.3 75.5 111.2 68.165.1 66.8 I_(max): Maximum intensity of luminescence, Int.: Relativeintensity of luminescence integrated for 60 seconds

Example 19: Construction of Secretory Expression Vector for the KAZMutants with Two Amino Acid Substitutions and Three Amino AcidSubstitutions Using a Signal Peptide Sequence of Gaussia Luciferase forSecretion

Vectors for the secretory expression of the KAZ mutants with two aminoacid substitutions and three amino acid substitutions were constructedusing the signal peptide sequence of Gaussia luciferase for secretion,as follows. Using the pcDNA3-GLsp-vector prepared in EXAMPLE 8, the genefragments of the KAZ mutants with two amino acid substitutions and threeamino acid substitutions prepared in EXAMPLE 12 and the dnKAZ genefragment prepared in EXAMPLE 2 were digested with restriction enzymesEcoRI/XbaI in a conventional manner, and ligated to the EcoRI-XbaI siteof pcDNA3-GLsp to construct the expression vectors ofpcDNA3-GLsp-KAZ-V44I-A54I, pcDNA3-GLsp-KAZ-V44I-Y138I,pcDNA3-GLsp-KAZ-A54I-Y138I, pcDNA3-GLsp-KAZ-V44I-A54I-Y138I andpcDAN3-GLsp-dnKAZ. The sequences of genes inserted were confirmed bysequencing using a DNA Sequencer (manufactured by ABI Inc.).

Example 20: Transfection of Vectors into Animal Culture Cells andPreparation of Enzyme for Assay (1) Purification of Expression Plasmids

The recombinant plasmids obtained in EXAMPLE 19 were purified in thesame manner as EXAMPLE 10 and dissolved in sterilied water. Fireflyluciferase vector (pGL4.13 [Luc2/sv40]: manufactured by Promega Corp.)was similarly treated and used as an internal standard.

(2) Transfection and Preparation of Enzyme Solutions for Assay

Culture media of the KAZ mutants with two amino acid substitutions andKAZ mutants with three amino acid substitutions and the enzyme solutionsof the cell-extracts of KAZ mutants were prepared in the same manner asEXAMPLE 10.

In the resultant enzyme solutions and the enzyme solutions of thecell-extracts of KAZ mutants, luminescence activities were determined inthe same manner as EXAMPLE 11.

The results are shown in TABLE 11. Based on the results of TABLE 11, theKAZ mutants with two amino acid substitutions and three amino acidsubstitutions expressed using the signal peptide sequence of Gaussialuciferase for secretion were hardly secreted from the cells as comparedto dnKAZ, in spite of being expressed in the cytoplasm.

TABLE 11 Luminescence activities of KAZ mutants expressed using vectorsfor secretory expression of KAZ mutants using the signal peptidesequence of Gaussia luciferase for secretion Relative LuminescenceActivity Expression Vector (%, I_(max)) (pcDNA3-GLsp-) Culture MediumCell Extracts KAZ less than 0.01 0.3 KAZ-V44I-A54I 0.07 13.9KAZ-V44I-Y138I less than 0.01 11.2 KAZ-A54I-Y138I 0.03 16.0KAZ-V44I-A54I-Y138I 1.7 16.2 dnKAZ 100 12.6

Example 21: Construction of Expression Vectors for KAZ Mutants with TwoAmino Acid Substitutions and Three Amino Acid Substitutions withoutSignal Peptide Sequence for Secretion in Animal Culture Cells

The gene fragments of the KAZ mutants with two amino acid substitutionsand three amino acid substitutions and nanoKAZ containing the Kozaksequence were digested with restriction enzymes Asp718 and XbaI, andinserted into the Asp718-XbaI site of pcDNA3 vector (manufactured byInvitrogen Inc.) to construct the vectors of pcDNA3-KAZ-V44I,pcDNA3-KAZ-A54I, pcDNA3-KAZ-Y138I, pcDNA3-KAZ-V44I-A54I,pcDNA3-KAZ-V44I-Y138I, pcDNA3-KAZ-A54I-Y138I andpcDNA3-KAZ-V44I-A54I-Y138I.

Example 22: Transfection of Vectors in Animal Culture Cells andPreparation of Enzyme Solution for Assay (1) Purification of ExpressionPlasmids

The recombinant plasmids obtained in EXAMPLE 21 were purified in thesame manner as EXAMPLE 10 and dissolved in sterile water. Fireflyluciferase vector (pGL4.13 [Luc2/sv40]: manufactured by Promega Corp.)was similarly treated and used as an internal standard.

(2) Transfection and Preparation of Enzyme for Assay

The culture media of the KAZ mutants with two amino acid substitutionsand KAZ mutants with three amino acid substitutions and the enzymesolutions of cell-extracts of KAZ mutants were obtained in the samemanner as EXAMPLE 10.

Luminescence activities of the resulting enzyme solutions and enzymesolutions of the cell-extracts of KAZ mutants were determined in thesame manner as EXAMPLE 11.

The results are shown in TABLE 12. It is understood from TABLE 12 thatthe KAZ mutants with two amino acid substitutions and three amino acidsubstitutions, which were expressed using the expression vectors for theKAZ mutants without a secretion signal, showed higher luminescenceactivities, specifically, KAZ-V44I was 3.7-fold higher, KAZ-A54I6.7-fold higher, KAZ-Y138I 6.4-fold higher, KAZ-V44I-A54I 23-foldhigher, KAZ-V44I-Y138I 15-fold higher, KAZ-A54I-Y138I 22-fold higher andKAZ-V44I-A54I-Y138I 56-fold higher in the cell extracts, than wild KAZ.In particular, the KAZ mutants with two amino acid substitutions and theKAZ mutants with three amino acid substitutions showed higher activitiesthan wild KAZ.

On the other hand, secretion from the cells was hardly observed in allof the mutants, notwithstanding that the luminescence activities werefound to be higher in the cytoplasm than wild KAZ.

TABLE 12 Luminescence activities of KAZ mutants using expression vectorsfor the KAZ mutants without a secretional signal peptide sequenceRelative Luminescence Activity Rate of Secretion Expression Vector(I_(max)) (Medium/Cell (pcDNA3-) Culture Medium Cell Extracts Extracts)KAZ 0.03 1.0 0.03 KAZ-V44I 0.06 3.7 0.016 KAZ-A54I 0.03 6.7 0.0045KAZ-Y138I 0.03 6.4 0.0047 KAZ-V44I-A54I 0.05 22.5 0.0022 KAZ-V44I-Y138I0.04 14.7 0.0026 KAZ-A54I-Y138I 0.05 21.5 0.0023 KAZ-V44I-A54I- 0.0856.0 0.0014 Y138I

These results reveal that the two amino acid substituted KAZ mutants ofKAZ-V44I-A54I, KAZ-V44I-Y138I and KAZ-A54I-Y138I and the three aminoacid substituted KAZ mutant of KAZ-V44I-A54I-Y138I showed markedlyhigher luminescence activities than wild KAZ when coelenterazine wasused as a substrate, and these mutants have the property that they arenot secreted from animal culture cells. The mutants are thereforesuitable for a reporter assay in the cytoplasm.

[Sequence Listing Free Text]

[SEQ ID NO: 1] Nucleotide sequence for KAZ[SEQ ID NO: 2] Amino acid sequence for KAZ[SEQ ID NO: 3] Nucleotide sequence for KAZ-V44I[SEQ ID NO: 4] Amino acid sequence for KAZ-V44I[SEQ ID NO: 5] Nucleotide sequence for KAZ-A54I[SEQ ID NO: 6] Amino acid sequence for KAZ-A54I[SEQ ID NO: 7] Nucleotide sequence for KAZ-Y138I[SEQ ID NO: 8] Amino acid sequence for KAZ-Y138I[SEQ ID NO: 9] Nucleotide sequence for KAZ-V44I-A54I[SEQ ID NO: 10] Amino acid sequence for KAZ-V44I-A54I[SEQ ID NO: 11] Nucleotide sequence for KAZ-V44I-Y138I[SEQ ID NO: 12] Amino acid sequence for KAZ-V44I-Y138I[SEQ ID NO: 13] Nucleotide sequence for KAZ-A54I-Y138I[SEQ ID NO: 14] Amino acid sequence for KAZ-A54I-Y138I[SEQ ID NO: 15] Nucleotide sequence for KAZ-V44I-A54I-Y138I[SEQ ID NO: 16] Amino acid sequence for KAZ-V44I-A54I-Y138I[SEQ ID NO: 17] Nucleotide sequence used in EXAMPLES (pCold-F)[SEQ ID NO: 18] Nucleotide sequence used in EXAMPLES (KAZ: Q18L-R)[SEQ ID NO: 19] Nucleotide sequence used in EXAMPLES (KAZ: Q18L-F)[SEQ ID NO: 20] Nucleotide sequence used in EXAMPLES (KAZ-5C/XbaI)[SEQ ID NO: 21] Nucleotide sequence used in EXAMPLES (KAZ-8N/EcoRI)[SEQ ID NO: 22] Nucleotide sequence used in EXAMPLES (KAZ: A4E-F)[SEQ ID NO: 23] Nucleotide sequence used in EXAMPLES (KAZ: Q11R-F)[SEQ ID NO: 24] Nucleotide sequence used in EXAMPLES (KAZ: L27V-R)[SEQ ID NO: 25] Nucleotide sequence used in EXAMPLES (KAZ: L27V-F)[SEQ ID NO: 26] Nucleotide sequence used in EXAMPLES (A33N-R)[SEQ ID NO: 27] Nucleotide sequence used in EXAMPLES (A33N-F)[SEQ ID NO: 28] Nucleotide sequence used in EXAMPLES (KAZ: K43R-R)[SEQ ID NO: 29] Nucleotide sequence used in EXAMPLES (KAZ: L43R-F)[SEQ ID NO: 30] Nucleotide sequence used in EXAMPLES (KAZ: V44I-R)[SEQ ID NO: 31] Nucleotide sequence used in EXAMPLES (KAZ: V44I-F)[SEQ ID NO: 32] Nucleotide sequence used in EXAMPLES (KAZ: A54I-R)[SEQ ID NO: 33] Nucleotide sequence used in EXAMPLES (KAZ: A54I-F)[SEQ ID NO: 34] Nucleotide sequence used in EXAMPLES (pCold-R)[SEQ ID NO: 35] Nucleotide sequence used in EXAMPLES (KAZ: F68D-R)[SEQ ID NO: 36] Nucleotide sequence used in EXAMPLES (KAZ: F68D-F)[SEQ ID NO: 37] Nucleotide sequence used in EXAMPLES (KAZ: L72Q-R)[SEQ ID NO: 38] Nucleotide sequence used in EXAMPLES (KAZ: L72Q-F)[SEQ ID NO: 39] Nucleotide sequence used in EXAMPLES (KAZ: M75K-R)[SEQ ID NO: 40] Nucleotide sequence used in EXAMPLES (KAZ: M75K-F)[SEQ ID NO: 41] Nucleotide sequence used in EXAMPLES (KAZ: I90V-R)[SEQ ID NO: 42] Nucleotide sequence used in EXAMPLES (KAZ: I90V-F)[SEQ ID NO: 43] Nucleotide sequence used in EXAMPLES (KAZ: P115E-R)[SEQ ID NO: 44] Nucleotide sequence used in EXAMPLES (KAZ: P115E-F)[SEQ ID NO: 45] Nucleotide sequence used in EXAMPLES (KAZ: Q124K-R)[SEQ ID NO: 46] Nucleotide sequence used in EXAMPLES (KAZ: Q124K-F)[SEQ ID NO: 47] Nucleotide sequence used in EXAMPLES (KAZ: Y138I-R)[SEQ ID NO: 48] Nucleotide sequence used in EXAMPLES (KAZ: Y138I-F)[SEQ ID NO: 49] Nucleotide sequence used in EXAMPLES (KAZ: N166R-R)[SEQ ID NO: 50] Nucleotide sequence used in EXAMPLES (nanoKAZ-1N/EcoRI)[SEQ ID NO: 51] Nucleotide sequence used in EXAMPLES (nanoKAZ-3C/XbaI)[SEQ ID NO: 52] Nucleotide sequence used in EXAMPLES (GLsp-1R/EcoRI)[SEQ ID NO: 53] Nucleotide sequence used in EXAMPLES (T7 primer)

1.-18. (canceled)
 19. A method for performing a luminescence reaction,which comprises contacting a luciferase mutant with a luciferin, whereinthe luciferase mutant is defined in (a) or (b) below: (a) a luciferasemutant comprising the amino acid sequence of SEQ ID NO: 2 substituted atthe positions consisting of the valine at position of 44, the alanine atposition 54 and the tyrosine at position 138, wherein the luciferasemutant has luciferase activity; and (b) a luciferase mutant comprisingthe amino acid sequence of SEQ ID NO: 2 substituted at the positionsconsisting of: (1) the valine at position of 44, the alanine at position54, and the tyrosine at position 138; and (2) one to sixteen positions,none of which includes any one of the positions 4, 11, 18, 27, 33, 43,68, 72, 75, 90, 115, 124, and 166, wherein the luciferase mutant hasluciferase activity.
 20. The method according to claim 19, wherein theluciferase mutant comprises the amino acid sequence of SEQ ID NO: 2substituted at the positions consisting of: (1) the valine at positionof 44, the alanine at position 54, and the tyrosine at position 138; and(2) one to ten positions, none of which includes any one of thepositions 4, 11, 18, 27, 33, 43, 68, 72, 75, 90, 115, 124, and
 166. 21.The method according to claim 19, wherein the valine at position of 44is substituted by isoleucine, the alanine at position 54 is substitutedby isoleucine, and the tyrosine at position 138 is substituted byisoleucine.
 22. The method according to claim 19, wherein the luciferasecomprises the amino acid sequence of SEQ ID NO:
 16. 23. The methodaccording to claim 19, wherein the luciferin is selected fromcoelenterazines.
 24. The method according to claim 23, wherein theluciferins is coelenterazine.